U.S. patent application number 15/281154 was filed with the patent office on 2017-05-11 for attenuated mannheimia haemolytica vaccines and methods of making and use.
The applicant listed for this patent is Biotechnology Research and Development Corporation, The United States of America as represented by the Secretary of Agriculture, The United States of America as represented by the Secretary of Agriculture. Invention is credited to Robert E. Briggs, Fred M. Tatum.
Application Number | 20170128560 15/281154 |
Document ID | / |
Family ID | 50685318 |
Filed Date | 2017-05-11 |
United States Patent
Application |
20170128560 |
Kind Code |
A1 |
Briggs; Robert E. ; et
al. |
May 11, 2017 |
Attenuated Mannheimia haemolytica Vaccines and Methods of Making
and Use
Abstract
The present invention provides attenuated M. haemolytica strains
that elicit an immune response in animals against M. haemolytica,
compositions comprising said strains, methods of vaccination
against M. haemolytica, and kits for use with such methods and
compositions. The invention further provides multi-valent vaccines,
which provide protective immunity when administered in an effective
amount to animals susceptible to "shipping fever" or bovine
respiratory disease.
Inventors: |
Briggs; Robert E.; (Boone,
IA) ; Tatum; Fred M.; (Ames, IA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Biotechnology Research and Development Corporation
The United States of America as represented by the Secretary of
Agriculture |
Peoria
Washington |
IL
DC |
US
US |
|
|
Family ID: |
50685318 |
Appl. No.: |
15/281154 |
Filed: |
September 30, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14934737 |
Nov 6, 2015 |
|
|
|
15281154 |
|
|
|
|
14075169 |
Nov 8, 2013 |
9370561 |
|
|
14934737 |
|
|
|
|
61723979 |
Nov 8, 2012 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 14/285 20130101;
A61K 2039/522 20130101; A61K 2039/543 20130101; A61K 2039/70
20130101; A61K 39/102 20130101; C12N 1/36 20130101; A61K 2039/552
20130101; A61P 31/04 20180101 |
International
Class: |
A61K 39/102 20060101
A61K039/102 |
Claims
1. A vaccine comprising an attenuated Mannheimia haemolytica (M.
haemolytica) A1 strain and an attenuated M. haemolytica A6 strain,
which vaccine provides a safe and protective immune response in a
bovine against both M. haemolytica strain A1 and M. haemolytica
strain A6, or diseases caused by M. haemolytica strains A1 and A6;
and wherein both the A1 and A6 strains contain nucleic acid
deletions in their respective leukotoxin A (lktA) genes, which
deletions have rendered the strains attenuated relative to the
virulent parental strains A1 and A6 from which the attenuated
strains A1 and A6 were produced.
2. The vaccine of claim 1, consisting essentially of the attenuated
strains.
3. The vaccine of claim 1, further comprising an adjuvant.
4. The vaccine of claim 1, wherein a safe and protective intranasal
dose of the vaccine comprises from about 1.19.times.10.sup.6 to
1.19.times.10.sup.7 CFU of the attenuated A1 strain and from about
9.2.times.10.sup.5 to 9.2x 10.sup.6 CFU of the attenuated A6
strain.
5. The vaccine of claim 4, further comprising a pharmaceutically or
veterinary acceptable vehicle, diluent or excipient and from about
1.19.times.10.sup.6 to 1.19.times.10.sup.7 CFU of the attenuated A1
strain and from about 9.2.times.10.sup.5 to 9.2.times.10.sup.6 CFU
of the attenuated A6 strain.
6. The vaccine of claim 5, further comprising an adjuvant.
7. The vaccine of claim 6, wherein the adjuvant is inactivated
bacteria, inactivated virus, fractions of inactivated bacteria,
bacterial lipopolysaccharides, bacterial toxins, or derivatives or
combinations thereof.
8. The vaccine of claim 4, which provides a protective immune
response in a bovine against an experimental challenge of about
2.4.times.10.sup.9 CFU of virulent M. haemolytica strain A1.
9. The vaccine of claim 1, further comprising at least one
additional antigen associated with a bovine pathogen other than M.
haemolytica.
10. A method of vaccinating an animal comprising administering at
least one dose of the vaccine of claim 1.
11. The method of claim 10, wherein the animal is a bovine.
12. The method of claim 11, wherein the bovine is a calf that is 28
days or older.
13. An immunological composition suitable for the prevention of
bovine respiratory disease caused by M. haemolytica, comprising the
vaccine of claim 1, and further comprising an immunologically
effective amount of attenuated Pasteurella multocida and
Histophilus somni.
14. The method of claim 10, wherein the vaccine is administered
intranasally.
Description
[0001] This application incorporates by reference the contents of a
61.8 kb text file created on Sep. 30, 2016 and named
"00848800006sequencelisting.txt," which is the sequence listing for
this application.
FIELD OF THE INVENTION
[0002] The present invention relates generally to attenuated
bacterial vaccines, particularly those providing broad, safe, and
effective protection to production animals against
infections/disease caused by gram-negative bacteria, including
Mannheimia (Pasteurella) haemolytica. The invention further relates
to methods of producing the attenuated bacteria, and to PCR methods
for differentiating among M. haemolytica serotypes A1 and A6, in
vivo.
[0003] The invention accordingly relates to immunogenic or vaccine
compositions comprising the bacteria of the invention; e.g., live
attenuated bacteria. The bacteria also could be inactivated in the
compositions, but it may be advantageous that the bacteria are live
attenuated M. haemolytica bacteria, either alone, or combined with
other bacteria such as Haemophilus somnus and/or Pasteurella
multocida. The invention therefore further relates to methods for
preparing and/or formulating such compositions; e.g., culturing or
growing or propagating the bacteria on or in suitable medium,
harvesting the bacteria, optionally inactivating the bacteria, and
optionally admixing the bacteria with a suitable veterinarily or
pharmaceutically acceptable carrier, excipient, diluent or vehicle
and/or an adjuvant and/or stabilizer. Thus, the invention also
relates to the use of the bacteria in formulating such
compositions.
BACKGROUND OF THE INVENTION
[0004] M. haemolytica is a gram negative bacterium normally found
in the upper respiratory tract of healthy cattle, sheep and wild
sheep. M. haemolytica descends into the lungs when cattle
experience stress such as shipping, weaning, overcrowding, or viral
infections and causes fibrinous and necrotizing bronchopneumonia, a
chief component of the bovine respiratory disease complex (BRDC).
Economic losses due to BRDC in North America is >$1 billion
annually (Bowland and Shewen, 2000). M. haemolytica is the
bacterium most commonly isolated from the lungs of cattle affected
with BRDC. M. haemolytica serotype AI is responsible for
approximately 60% of shipping fever, whereas serotypes A6 and A2
account for 26% and 7% respectively (Al-Gharndi et al., 2000; Purdy
et al., 1997). Both M. haemolytica A1 and A6 account for >85% of
BRDC cases involving bacterial pathogens.
[0005] The vaccines currently available in the market against M.
haemolytica infections are only moderately protective against
shipping fever of beef cattle but generally ineffective against
neonatal dairy calf pneumonia (Virtala et al., 1996; Rice et al.,
2007). The major cause of severe bacterial pneumonia in feedlot and
neonatal dairy cattle is M. haemolytica serotype A1 followed by
serotype A6 (Schreuer et al., 2000, Rice et al., 2007).
[0006] Experimental evaluation of all the commercial M. haemolytica
A1 vaccines used in feedlot showed only partial protection in 50%
of the studies (Perino and Hunsaker, 1997). Furthermore,
cross-protection against M. haemolytica serotypes (either A6 or A2)
has been difficult to achieve using conventional vaccine
preparations (Purdy et al., 1993; Sabri et al., 2000). Therefore,
an efficacious vaccine against M. haemolytica serotypes A1 and A6
could significantly improve dairy/beef production.
[0007] Effective immunity against M. haemolytica is multifaceted.
Neutralizing Antibodies against exotoxin leukotoxin A (LktA) and
surface antigens are necessary for protective immunity against M.
haemolytica (Shewen and Wilkie, 1988). Due to the complex genetic
machinery involved in controlling the expression of various M.
haemolytica virulence factors, the specific surface antigens that
are important in stimulating immunity have not been clearly
determined (Lawrence et al, 2010). However, M. haemolytica outer
membrane proteins (OMPs) have been implicated in stimulating
immunity against surface antigens (Confer et al., 2003, Morton et
al., 1995; Potter et al., 1999).
[0008] Intranasal immunization of cattle has been pursued for a
while using bovine herpesvirus-1 (BoUV-1), bovine respiratory
syncytial virus (BRSV) and infectious bovine rhinotracheitis virus
(IBR) (Ellis et al., 2007; Muylkens et al., 2007). Commercially
available Pfizer's INFORCE 3 when administered intranasally claims
to prevent BRSV and also aids in the prevention of respiratory
disease caused by IBR and bovine parainfluenza virus type 3
(PI3).
[0009] In an experimental study when a modified live leukotoxin
deficient M. haemolytica mutant was administered intranasally in
weaned beef feedlot calves, it resulted in reduced nasopharyngeal
colonization with wild type M. haemolytica compared to
non-vaccinated control calves (Frank et al., 2003). Although
intranasal vaccination and leukotoxin deficient M. haemolytica are
known, inventors are aware of no M. haemolytica vaccines
successfully combining these concepts.
SUMMARY OF THE INVENTION
[0010] An object of the present disclosure is to provide effective
vaccines comprising attenuated M. haemolytica serotypes A1 &
A6. Relative to a parent M haemolytica serotype AI or A6 strain,
the attenuated strains may have genomic modifications, including
deletions, substitutions, and additions, and whose presence (or
absence) is associated with reduced virulence. In an embodiment, a
wildtype M. haemolytica (serotype AI DI53) may be modified to
contain a partial gene deletion of the leukotoxin CA (IktCA)
genomic locus, resulting in an attenuated bacterium, which secretes
a truncated, noncytotoxic form of LktA protein. The vaccines
ideally provide safe, effective, and broad protective immunity.
[0011] Another object of the disclosure is to provide multi-valent
vaccines, comprising the attenuated M haemolytica in combination
with other bacteria, including P. multocida, M. haemolytica
serotype A6, and Histophilus somni (H. somni). Thus, the invention
encompasses a 4-way avirulent, modified live vaccine useful against
bovine respiratory disease.
[0012] A further object of this invention is to provide methods for
treatment and prophylaxis of infection bovine respiratory disease,
comprising the steps of administering effective amounts of the
inventive vaccines to susceptible bovine animals.
[0013] In one embodiment, the attenuated vaccines further comprises
an adjuvant. The adjuvant may be any substance which increases
and/or augments the elicited immune response, as compared to
attenuated vaccine alone. Mucosal adjuvants, including chitosans
and derivatives thereof, are particularly useful for the disclosed
oral attenuated vaccines.
[0014] The invention further provides methods for inducing an
immunological (or immunogenic) or protective response against M.
haemolytica, as well as methods for preventing or treating M.
haemolytica, or disease state(s) caused by M. haemolytica,
comprising administering the attenuated bacteria, or a composition
comprising the attenuated bacteria to animals in need thereof.
[0015] In addition, the disclosure provides PCR methods and
reagents useful for diagnosing and/or discriminating between M.
haemolytica serotypes A1 and A6. Comparative genomic sequence
analysis, further described below, revealed A1- and A6-specific
genes, which provide the basis for the methods and reagents
provided in this disclosure.
[0016] Kits comprising at least the attenuated M. haemolytica
strain and instructions for use are also provided.
[0017] These and other embodiments are disclosed or are obvious
from and encompassed by, the following Detailed Description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0018] A full and enabling disclosure of the present invention,
including the best mode thereof, to one of ordinary skill in the
art, is set forth more particularly in the remainder of the
specification, including reference to the accompanying figures,
wherein:
[0019] FIG. 1 presents the scheme used to produce the
pCT109GA189.DELTA.lktCA-Kan plasmid (replacement plasmid). The
final product for vaccine manufacture incorporated a consensus
ribosome-binding site (AGGAGG, rbs) upstream of the start codon
which replaced the poor lktC rbs and increased expression of
leukotoxoid. The native lktA gene, deleted in the vaccine strain,
uses a strong rbs (AGGAGA). For this product, lktRBSr primer was
used in-lieu of lktCAdelr primer. The consensus site is
underlined;
[0020] FIG. 2 illustrates integration of the replacement plasmid
into the bacterial genome;
[0021] FIG. 3 depicts resolution/excision of the replacement
plasmid, leaving behind only the desired .DELTA.lktCA sequence,
stably integrated into the bacterial genome, and encoding the
truncated LktA protein;
[0022] FIG. 4A agarose gel electrophoresis of PCR products from M.
haemolytica LktCABD operon showing truncated LktCA (lane 2) and
wildtype LktCA (lane 3);
[0023] FIG. 4B Western blot analysis of truncated LktA expressed by
M. haemolytica D153.DELTA.-1-PKL, vaccine strain. Lanes: 1- marker;
2-5 .mu.l of culture supernatant containing truncated LktA (*=27
kDa, M. haemolytica D153.DELTA.-1-PKL); 3-5 .mu.l of culture
supernatant containing wildtype LktA (*=102 kDa, M. haemolytica
D153 parent strain);
[0024] FIG. 5 is a Venn diagram representing the unique and
overlapping genes present in five M. haemolytica isolates.
DETAILED DESCRIPTION OF TIRE INVENTION
[0025] The present invention relates to a M. haemolytica vaccine or
composition which may comprise an attenuated M. haemolytica strain
and a pharmaceutically or veterinarily acceptable carrier,
excipient, or vehicle, which elicits, induces or stimulates a
response in an animal.
[0026] In order to develop an effective M. haemolytica intranasal
vaccine, which protects bovines against serogroups A1/A6, inventors
used M. haemolytica having a partially deleted LktA gene. This
bacterium does not cause cytolysis, but is able to elicit
neutralizing antibodies. Prior to the instant disclosure, it was
not known whether intranasal administration (or administration via
any route) would elicit in bovines a protective immune
response.
[0027] Although there are serological methods to distinguish M.
haemolytica A1 and A6 these methods are not always reliable and
developing strong antisera against A6 is particularly difficult. To
overcome this problem, inventors sequenced both A1 and A6 genomes,
performed a comparative genomic analysis and developed a real time
quantitative polymerase chain reaction (RT-QPCR) method to
distinguish between A1 and A6 field isolates and to track our
intranasal vaccine combination (M. haemolytica, M. somnus, and P.
multocida).
[0028] Thus, an embodiment of this disclosure provides useful
RT-QPCR methods, which enable at least the following activities: a)
identification of field isolates of M. haemolytica A1 and A6
quickly and screen large number of colonies; b) monitoring of
vaccination/colonization of A1 and A6 in nasal cavities; c)
elimination of the need for developing high titer antisera; and d)
development of rapid, automated diagnostic test kits.
[0029] The present invention further provides attenuated M.
haemolytica strains having a deletion in at least one virulence
gene. In an embodiment, the deletion is within LktCA, a locus that
encodes an enzyme acylase (LktC) and leukotoxin A (LktA), the chief
cytotoxin. This deletion may be amplified by polymerase chain
reaction (PCR) and the secretion of a truncated LktA can be
detected on a Western blot to determine if the bacterium is the
mutant or wildtype.
[0030] Deletion of genomic sequence(s) from virulent parental
bacteria to produce avirutent, attenuated mutant bacteria is
accomplished through novel and non-Obvious inventive activity. Such
mutant bacteria, also referred to herein as modified-live
microorganisms (MLNI) are useful for the production of immunogenic
compositions or vaccines having both a high degree of
immunogenicity and a low (to non-existent) degree of
pathogenicity.
[0031] These mutants are also useful as vectors which can be useful
for expression in vitro of expression products, as well as for
reproduction or replication of nucleotide sequences e.g.,
replication of DNA), and for in vivo expression products.
[0032] Engineering of the deletion mutations provides novel and
nonobvious nucleotide sequences and genes, as well as novel and
nonobvious gene products encoded by the nucleotide sequences and
genes. Such gene products provide antigens, immunogens and
epitopes, and are useful as isolated gene products. Such isolated
gene products, as well as epitopes thereof, are also useful for
generating antibodies, which are useful in diagnostic
applications.
[0033] Such gene products, which can provide or generate epitopes,
antigens or immunogens, are also useful for immunogenic or
immunological compositions, as well as vaccines.
[0034] In an aspect, the invention provides bacteria containing an
attenuating mutation in a nucleotide sequence or a gene wherein the
mutation modifies, reduces or abolishes the expression and/or the
biological activity of a polypeptide or protein encoded by a gene,
resulting in attenuated virulence of the bacterium. In a particular
embodiment, the mutation is an in-frame deletion resulting in the
bacterium secreting a truncated leukotoxin. In a particular
embodiment, the truncated leukotoxin migrates at about 27 kD on a
typical SDS gel.
[0035] Attenuation reduces or abolishes the pathogenicity of the
bacteria and the gravity of the clinical signs or lesions,
decreases the growth rate of the bacteria, and prevents the death
from the bacteria.
[0036] In particular, the present invention encompasses attenuated
M. haemolytica strains and vaccines comprising the same, which
elicit an immunogenic response in an animal, particularly the
attenuated M. haemolytica strains that elicit, induce or stimulate
a response in a bovine.
[0037] Particular M. haemolytica attenuated strains of interest
have mutations in genes, relative to wild type virulent parent
strain, which are associated with virulence. It is recognized that,
in addition to strains having the disclosed mutations, attenuated
strains having any number of mutations in the disclosed virulence
genes can be used in the practice of this invention.
[0038] In another aspect, the novel attenuated M. haemolytica
strains are formulated into safe, effective vaccine against M.
haemolytica and infections/diseases cause by M. haemolytica.
[0039] In an embodiment, the M. haemolytica vaccines further
comprise an adjuvant. In a particular embodiment, the adjuvant is a
mucosal adjuvant, such as chitosan, methylated chitosan,
trimethylated chitosan, or derivatives or combinations thereof.
[0040] As defined herein, the term "gene" will be used in a broad
sense, and shall encompass both coding and non-coding sequences 6.c
upstream and downstream regulatory sequences, promoters, 5'/3' UTR,
introns, and exons). Where reference to only a gene's coding
sequence is intended, the term "gene's coding sequence" or "CDS"
wilt be used interchangeably throughout this disclosure.
[0041] By "antigen" or "immunogen" means a substance that induces a
specific immune response in a host animal. The antigen may comprise
a whole organism, killed, attenuated or live; a subunit or portion
of an organism; a recombinant vector containing an insert with
immunogenic properties; apiece or fragment of DNA capable of
inducing an immune response upon presentation to a host animal; a
potypeptide, an epitope, a hapten, or any combination thereof.
Alternately, the immunogen or antigen may comprise a toxin or
antitoxin.
[0042] The terms "protein", "peptide", "polypeptide" and
"polypeptide fragment" are used interchangeably herein to refer to
polymers of amino acid residues of any length. The polymer can be
linear or branched, it may comprise modified amino acids or amino
acid analogs, and it may be interrupted by chemical moieties other
than amino acids. The terms also encompass an amino acid polymer
that has been modified naturally or by intervention; for example
disulfide bond formation, glycosylation, lipidation, acetylation,
phosphorylation, or any other manipulation or modification, such as
conjugation with a labeling or bioactive component.
[0043] The term "immunogenic or antigenic polypeptide" as used
herein includes polypeptides that are immunologically active in the
sense that once administered to the host, it is able to evoke an
immune response of the humoral and/or cellular type directed
against the protein. Preferably the protein fragment is such that
it has substantially the same immunological activity as the total
protein. Thus, a protein fragment according to the invention
comprises or consists essentially of or consists of at least one
epitope or antigenic determinant An "immunogenic" protein or
polypeptide, as used herein, includes the full-length sequence of
the protein, analogs thereof or immunogenic fragments thereof. By
"immunogenic fragment" is meant a fragment of a protein which
includes one or more epitopes and thus elicits the immunological
response described above. Such fragments can be identified using
any number of epitope mapping techniques, well known in the art.
See, e.g., Epitope Mapping Protocols in Methods in Molecular
Biology, Vol. 66 (Glenn E. Morris, Ed., 1996). For example, linear
epitopes may be determined by e.g., concurrently synthesizing large
numbers of peptides on solid supports, the peptides corresponding
to portions of the protein molecule, and reacting the peptides with
antibodies while the peptides are still attached to the supports.
Such techniques are known in the art and described in, e.g., U.S.
Pat. No. 4,708,871; Geysen et al., 1984; Geysen et al,, 1986.
Similarly, conformational epitopes are readily identified by
determining spatial conformation of amino acids such as by, e.g.,
x-ray crystallography and 2-dimensional nuclear magnetic resonance.
See, e.g., Epitope Mapping Protocols, supra. Methods especially
applicable to the proteins of T. parva are fully described in
PCT/US2004/022605 incorporated herein by reference in its
entirety.
[0044] As discussed herein, the invention encompasses active
fragments and variants of the antigenic polypeptide. Thus, the term
"immunogenic or antigenic polypeptide" further contemplates
deletions, additions and substitutions to the sequence, so long as
the polypeptide functions to produce an immunological response as
defined herein. The term "conservative variation" denotes the
replacement of an amino acid residue by another biologically
similar residue, or the replacement of a nucleotide in a nucleic
acid sequence such that the encoded amino acid residue does not
change or is another biologically similar residue. In this regard,
particularly preferred substitutions will generally be conservative
in nature, i.e., those substitutions that take place within a
family of amino acids. For example, amino acids are generally
divided into four families: (1) acidic--aspartate and glutamate;
(2) basic--lysine, arginine, histidine; (3) non-polar--alanine,
valine, leucine, isoleucine, proline, phenylalanine, methionine,
tryptophan; and (4) uncharged polar--glycine, asparagine,
glutamine, cystine, serine, threonine, tyrosine. Phenylalanine,
tryptophan, and tyrosine are sometimes classified as aromatic amino
acids. Examples of conservative variations include the substitution
of one hydrophobic 3( )residue such as isoleucine, valine, leucine
or methionine for another hydrophobic residue, or the substitution
of one polar residue for another polar residue, such as the
substitution of arginine for lysine, glutamic acid for aspartic
acid, or glutamine for asparagine, and the like; or a similar
conservative replacement of an amino acid with a structurally
related amino acid that will not have a major effect on the
biological activity. Proteins having substantially the same amino
acid sequence as the reference molecule but possessing minor amino
acid substitutions that do not substantially affect the
immunogenicity of the protein are, therefore, within the definition
of the reference polypeptide. All of the polypeptides produced by
these modifications are included herein. The term "conservative
variation" also includes the use of a substituted amino acid in
place of an unsubstituted parent amino acid provided that
antibodies raised to the substituted polypeptide also immunoreact
with the unsubstituted polypeptide.
[0045] The term "epitope" refers to the site on an antigen or
hapten to which specific B cells and/or T cells respond. The term
is also used interchangeably with "antigenic determinant" or
"antigenic determinant site". Antibodies that recognize the same
epitope can be identified in a simple immunoassay showing the
ability of one antibody to block the binding of another antibody to
a target antigen.
[0046] An "immunological response" to a composition or vaccine is
the development in the host of a cellular and/or antibody-mediated
immune response to a composition or vaccine of interest. Usually,
an "immunological response" includes but is not limited to one or
more of the following effects: the production of antibodies, B
cells, helper T cells, and/or cytotoxic T cells, directed
specifically to an antigen or antigens included in the composition
or vaccine of interest. Preferably, the host will display either a
therapeutic or protective immunological response such that
resistance to new infection will be enhanced and/or the clinical
severity of the disease reduced. Such protection will be
demonstrated by either a reduction or lack of symptoms and/or
clinical disease signs normally displayed by an infected host, a
quicker recovery time and/or a lowered viral titer in the infected
host.
[0047] By "animal" is intended mammals, birds, and the like. Animal
or host as used herein includes mammals and human. The animal may
be selected from the group consisting of equine (e.g., horse),
canine (e.g., dogs, wolves, foxes, coyotes, jackals), feline (e.g.,
lions, tigers, domestic cats, wild cats, other big cats, and other
felines including cheetahs and lynx), ovine (e.g., sheep), bovine
(e.g., cattle), porcine (e.g., pig), avian (e.g., chicken, duck,
goose, turkey, quail, pheasant, parrot, finches, hawk, crow,
ostrich, emu and cassowary), primate (e.g., prosimian, tarsier,
monkey, gibbon, ape), ferrets, seals, and fish. The term "animal"
also includes an individual animal in all stages of development,
including newborn, embryonic and fetal stages.
[0048] Unless otherwise explained, all technical and scientific
terms used herein have the same meaning as commonly understood by
one of ordinary skill in the art to which this disclosure belongs.
The singular terms "a", "an", and "the" include plural referents
unless context clearly indicates otherwise. Similarly, the word
"or" is intended to include "and" unless the context clearly
indicate otherwise.
[0049] It is noted that in this disclosure and particularly in the
claims and/or paragraphs, terms such as "comprises", "comprised",
"comprising" and the like can have the meaning attributed to it in
U.S. Patent law; e.g., they can mean "includes", "included",
"including", and the like; and that terms such as "consisting
essentially of" and "consists essentially of" have the meaning
ascribed to them in U.S. Patent law, e.g., they allow for elements
not explicitly recited, but exclude elements that are found in the
prior art or that affect a basic or novel characteristic of the
invention.
[0050] The term "nucleic acid" and "polynucleotide" refers to RNA
or DNA that is linear or branched, single or double stranded, or a
hybrid thereof. The term also encompasses RNA/DNA hybrids. The
following are non-limiting examples of polynucleotides: a gene or
gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA,
recombinant polynucleotides, branched polynucleotides, plasmids,
vectors, isolated DNA of any sequence, isolated RNA of any
sequence, nucleic acid probes and primers. A polynucleotide may
comprise modified nucleotides, such as methylated nucleotides and
nucleotide analogs, uracyl, other sugars and linking groups such as
fluororibose and thiolate, and nucleotide branches. The sequence of
nucleotides may be further modified after polymerization, such as
by conjugation, with a labeling component. Other types of
modifications included in this definition are caps, substitution of
one or more of the naturally occurring nucleotides with an analog,
and introduction of means for attaching the polynucleotide to
proteins, metal ions, labeling components, other polynucleotides or
solid support. The polynucleotides can be obtained by chemical
synthesis or derived from a microorganism.
[0051] The term "gene" is used broadly to refer to any segment of
polynucleotide associated with a biological function. Thus, genes
include introns and exons as in genomic sequence, or just the
coding sequences as in cDNAs and/or the regulatory sequences
required for their expression. For example, gene also refers to a
nucleic acid fragment that expresses mRNA or functional RNA, or
encodes a specific protein, and which includes regulatory
sequences.
[0052] An "isolated" biological component (such as a nucleic acid
or protein or organelle) refers to a component that has been
substantially separated or purified away from other biological
components in the cell of the organism in which the component
naturally occurs, for instance, other chromosomal and
extra-chromosomal DNA and RNA, proteins, and organelles. Nucleic
acids and proteins that have been "isolated" include nucleic acids
and proteins purified by standard purification methods. The term
also embraces nucleic acids and proteins prepared by recombinant
technology as well as chemical synthesis.
[0053] The term "conservative variation" denotes the replacement of
an amino acid residue by another biologically similar residue, or
the replacement of a nucleotide in a nucleic acid sequence such
that the encoded amino acid residue does not change or is another
biologically similar residue. In this regard, particularly
preferred substitutions will generally be conservative in nature,
as described above.
[0054] The term "recombinant" means a polynucleotide with
semisynthetic, or synthetic origin which either does not occur in
nature or is linked to another polynucleotide in an arrangement not
found in nature.
[0055] "Heterologous" means derived from a genetically distinct
entity from the rest of the entity to which it is being compared.
For example, a polynucleotide may be placed by genetic engineering
techniques into a plasmid or vector derived from a different
source, and is a heterologous polynucleotide. A promoter removed
from its native coding sequence and operatively linked to a coding
sequence other than the native sequence is a heterologous
promoter.
[0056] The polynucleotides of the invention may comprise additional
sequences, such as additional encoding sequences within the same
transcription unit, controlling elements such as promoters,
ribosome binding sites, 5'UTR, 3'UTR, transcription terminators,
polyadenylation sites, additional transcription units under control
of the same or a different promoter, sequences that permit cloning,
expression, homologous recombination, and transformation of a host
cell, and any such construct as may be desirable to provide
embodiments of this invention.
Methods of Use and Article of Manufacture
[0057] The present invention includes the following method
embodiments. In an embodiment, a method of vaccinating an animal
comprising administering a composition comprising an attenuated M.
haemolytica strain and a pharmaceutical or veterinarily acceptable
carrier, excipient, or vehicle to an animal is disclosed. In one
aspect of this embodiment, the animal is a bovine.
[0058] The dose volume of compositions for target species that are
mammals, e.g., the dose volume of pig or swine compositions, based
on bacterial antigens, is generally between about 0.1 to about 2.0
ml, between about 0.1 to about 1.0 ml, and between about 0.5 ml to
about 1.0 ml.
[0059] The efficacy of the vaccines may be tested about 2 to 4
weeks after the last immunization by challenging animals, such as
bovine, with a virulent strain of M. haemolytica. Both homologous
and heterologous strains are used for challenge to test the
efficacy of the vaccine. The animal may be challenged by IM or SC
injection, spray, intra-nasally, infra-ocularly; intra-tracheally,
and/or orally. Samples from joints, lungs, brain, and/or mouth may
be collected before and post-challenge and may be analyzed for the
presence of M. haemolytica-specific antibody.
[0060] The compositions comprising the attenuated bacterial strains
of the invention used in the prime-boost protocols are contained in
a pharmaceutically or veterinary acceptable vehicle, diluent or
excipient. The protocols of the invention protect the animal from
M. haemolytica and/or prevent disease progression in an infected
animal.
[0061] The various administrations are preferably carried out 1 to
6 weeks apart. Preferred time interval is 3 to 5 weeks, and
optimally 4 weeks according to one embodiment, an annual booster is
also envisioned. The animals, for example pigs, may be at least 3-4
weeks of age at the time of the first administration.
[0062] It should be understood by one of skill in the art that the
disclosure herein is provided by way of example and the present
invention is not limited thereto. From the disclosure herein and
the knowledge in the art, the skilled artisan can determine the
number of administrations, the administration route, and the doses
to be used for each injection protocol, without any undue
experimentation.
[0063] Another embodiment of the invention is a kit for performing
a method of eliciting or inducing an immunological or protective
response against M. haemolytica in an animal comprising an
attenuated M. haemolytica immunological composition or vaccine and
instructions for performing the method of delivery in an effective
amount for eliciting an immune response in the animal.
[0064] Another embodiment of the invention is a kit for performing
a method of inducing an immunological or protective response
against M. haemolytica in an animal comprising a composition or
vaccine comprising an attenuated M. haemolytica strain of the
invention, and instructions for performing the method of delivery
in an effective amount for eliciting an immune response in the
animal.
[0065] Yet another aspect of the present invention relates to a kit
for prime-boost vaccination according to the present invention as
described above. The kit may comprise at least two vials: a first
vial containing a vaccine or composition for the prime-vaccination
according to the present invention, and a second vial containing a
vaccine or composition for the boost-vaccination according to the
present invention. The kit may advantageously contain additional
first or second vials for additional prime-vaccinations or
additional boost-vaccinations.
[0066] The pharmaceutically or veterinarily acceptable carriers or
vehicles or excipients are well known to the one skilled in the
art. For example, a pharmaceutically or veterinarily acceptable
carrier or vehicle or excipient can be a 0.9% NaCl (e.g., saline)
solution or a phosphate buffer. Other pharmaceutically or
veterinarily acceptable carrier or vehicle or excipients that can
be used for methods of this invention include, but are not limited
to, poly-(L-glutamate) or polyvinylpyrrolidone. The
pharmaceutically or veterinarily acceptable carrier or vehicle or
excipients may be any compound or combination of compounds
facilitating the administration of the vector (or protein expressed
from an inventive vector in vitro); advantageously, the carrier,
vehicle or excipient may facilitate transfection and/or improve
preservation of the vector (or protein). Doses and dose volumes are
herein discussed in the general description and can also be
determined by the skilled artisan from this disclosure read in
conjunction with the knowledge in the art, without any undue
experimentation.
[0067] The immunological compositions and vaccines according to the
invention may comprise or consist essentially of one or more
adjuvants. Suitable adjuvants for use in the practice of the
present invention are (1) polymers of acrylic or methacrylic acid,
maleic anhydride and alkenyl derivative polymers, (2)
immunostimulating sequences (ISS), such as oligodeoxyribonucleotide
sequences having one or more non-methylated CpG units (Klinman et
al., 1996; WO98/16247), (3) an oil in water emulsion, such as the
SPT emulsion described on page 147 of "Vaccine Design, The Subunit
and Adjuvant Approach" published by M. Powell, M. Newman, Plenum
Press 1995, and the emulsion MF59 described on page 183 of the same
work, (4) cationic lipids containing a quaternary ammonium salt,
e.g., DDA (5) cytokines, (6) aluminum hydroxide or aluminum
phosphate, (7) saponin or (8) other adjuvants discussed in any
document cited and incorporated by reference into the instant
application, or (9) any combinations or mixtures thereof.
[0068] In an embodiment, adjuvants include those which promote
improved absorption through mucosal linings. Some examples include
MPL, LTK63, toxins, PLG microparticles and several others (Vajdy,
M. Immunology and Cell Biology (2004) 82, 617-627). In an
embodiment, the adjuvant may be a chitosan (Van der Lubben et al.
2001; Patel et al. 2005; Maj et al. 2008; U.S. Pat. No.
5,980.912).
[0069] In an embodiment, the adjuvant may be inactivated bacteria,
an inactivated virus, fractions of inactivated bacteria, bacterial
lipopolysaccharides, bacterial toxins, or derivatives or
REFERENCES
[0070] Ackermann, M. R, Brogden, K. A. 2000. Response of the
ruminant respiratory tract to Mannheimia (Pasteurella) haemolytica.
Microbes Infect. 2:1079-1088. [0071] Al-Ghamdi, G. M., et al, 2000,
Serotyping of Mannheimia (Pasteurella) haemolytica isolates from
the upper Midwest United States. J. Vet. Diagn. Invest. 12,
576-578. [0072] Bowland, S., Shewen, P., 2000. Bovine respiratory
disease: commercial vaccines currently available in Canda. Can.
Vet. J. 41, 33-38. [0073] Briggs R. E, Tatum F. M. 2005. Generation
and molecular characterization of new temperature-sensitive
plasmids intended for genetic engineering of Pasteurellaceae. Appl
Environ Micobiol 71:7187-7195. [0074] Burriel, A. R. 1997. News
& Notes: Isolation of Pasteurella haemolytica from Grass,
Drinking Water, and Straw Bedding Used by Sheep. Curr. Microbiol.
35: 316-318. [0075] Confer, A. W., et al., 2003. immunogenicity of
recombinant Mannheimia haemolytica serotype 1 outer membrane
protein PlpE and augmentation of a commercial vaccine. Vaccine 21,
2821-2829. [0076] Davies, R. L, et al. 2002. Mosaic structure and
molecular evolution of the leukotoxin operon (IktCABD) in
Mannheimia (Pasteurella) haemolytica, Mannheimia glueosida, and
Pasteurella trehalosi. J Bacteriol. 184(1):266-277. [0077] Davies,
R. L, et al. 2001. Sequence diversity and molecular evolution of
the leukotoxin (lktA) gene in bovine and ovine strains of
Mannheimia (Pasteurella) haemolytica. J Bacteriol.
183(4):1394-1404. [0078] Ellis, J., et al., 2007. Response of
calves to challenge exposure with virulent bovine respiratory
syncytial virus following intranasal administration of vaccines
formulated for parenteral administration. J. Am. Vet. Med. Assoc.
230, 233-243. [0079] Frank, G. H, et al. 2003. Effect of intranasal
exposure to leukotoxin-deficient Mannheimia haemolytica at the time
of arrival at the feedyard on subsequent isolation of M.
haemolytica from nasal secretions of calves. Am J Vet Res.
64(5):580-585. [0080] Gioia, J. et al. 2006. The genome sequence of
Mannheimia haemolytica A1: insights into virulence, natural
competence, and Pasteurellaceae phylogeny. J Bacteriol.
188(20):7257-7266. [0081] Lawrence, P. K., et al., 2010. Three-way
comparative genomic analysis of two Mannheimia haemolytica
isolates. BMC Genomics, 11:535 (Open access) [0082] Morton, R. J.,
et al., 1995. Vaccination of cattle with outer membrane
protein-enriched fractions of Pasteurella haemolytica and
resistance against experimental challenge exposure. Am. J. Vet.
Res. 56, 875-879. [0083] Miller, M. W. 2001. Pasteurellosis, In E.
S. Williams and I. K. Barker (ed.), Infectious diseases of wild
mammals. Iowa State University. Press, Ames, Iowa. p. 330-339
[0084] Mosier, D. A. 1997. Bacterial pneumonia, Vet. Clin, N. Am.
Food Anim, Pract, 13:483-493. [0085] Muylkens, B., et al., 2007.
Bovine herpesvirus 1 infection and infectious bovine
rhinotracheitis. Vet. Res. 38, 181-209. [0086] Potter, A. A., et
al., 1999. Protective capacity of the Pasteurella haemolytica
transferrin-binding proteins TbpA and TbpB in cattle. Microb Pathog
27, 197-206. [0087] Perino, L. J., Hunsaker, B. D., 1997. A review
of bovine respiratory disease vaccine field efficacy. The Bovine
Practitioner 31, 59-66. [0088] Purdy, C. W., et al, 1993. Efficacy
of Pasteurella haemolytica subunit antigens in a goat model of
pasteurellosis. Am. J. Vet. Res. 54, 1637-1647. [0089] Purdy, C.
W., et al., 1997. Efficacy of a subcutaneously administered,
ultraviolet light-killed Pasteurella multocida A:3-containing
bacterin against transthoracic challenge exposure in goats. Am. J.
Vet. Res. 58, 841-847. [0090] Rehmtulla, A. J, Thomson, R. G. 1981.
A review of the lesions in shipping fever of cattle. Can. Vet. J.
22:1 [0091] Rice, J. A., et al., 2007. Mannheimia haemolytica and
bovine respiratory disease. Anim. Health Res. Rev. 8, 117-128.
[0092] Sabri, M. Y., et al., 2000. Efficacy of an outer membrane
protein of Pasteurella haemolytica A2, A7 or A9-enriched vaccine
against intratracheal challenge exposure in sheep. Vet. Microbiol.
73, 13-23.
[0093] Schreuer, D., et al. 2000. Evaluation of the efficacy of a
new combined (Pasteurella) Mannheimia haemolytica serotype A1 and
A6 vaccine in pre-ruminant calves by virulent challenge. Journal
Cattle Practice Vol. 8 No. 1 pp. 9-12 [0094] Shewen, P. E., Wilkie,
B. N., 1988. Vaccination of calves with leukotoxic culture
supernatant from Pasteurella haemolytica. Can. J. Vet. Res. 52,
30-36. [0095] Virtala, A. M., et al., 1996. Epidemiologic and
pathologic characteristics of respiratory tract disease in dairy
heifers during the first three months of life. J. Am. Vet. Med.
Assoc. 208, 2035-2042.
[0096] The invention will now be further described by way of the
following non-limiting examples.
EXAMPLES
Example 1
Production of Attenuated M. haemolytica
[0097] M. haemolytica is a commensal organism of the upper
respiratory tract of calves and other ruminants. Under stress and
in immunocompromised animals M. haemolytica descends into lungs and
causes severe systemic disease resulting in pneumonic
pasteurellosis or "shipping fever". The pathogen can be spread by
nose to nose contact. To attenuate the bacterium, we deleted
nucleotides within the LktCA locus, which encodes an enzyme acylase
(LktC) and leukotoxin A (LktA), the bacterium's chief cytotoxin.
This deletion can be amplified by polymerase chain reaction (PCR)
and the secretion of a truncated LktA can be detected on a Western
blot to determine if the bacterium is the mutant or wildtype. The
genetic engineering is summarized in FIGS. 1-3. All reagents,
including the shuttle vectors pCR2.1, pBC SK, pSK, and pCT109GA189
ts ori, and the E. coli DH11S host cell, are well-known to and
accessible by persons skilled in the art.
[0098] Construction of lktCA deletion. pCT109GA189-Kan.DELTA.lktCA
and pCT109GA189-Kan.DELTA.lktCA-rbs were constructed as outlined in
FIGS. 1-3. Briefly, two DNA fragments, upstream (1.06 kb, SEQ ID
NO:6) and downstream (1.29 kb, SEQ ID NO:7) were PCR amplified from
M. haemolytica strain NADC D153 (FIG. 1). Whole cells were used as
template using the primer sets, lktCAf (SEQ ID NO:1)/lktCAdelr (SEQ
ID NO:4) and lktCAr (SEQ ID NO:2)/lktCAdelf (SEQ ID NO:3). The PCR
products were phenol-chloroform-extracted to inactivate Taq
polymerase and then digested with Muni prior to ligation. The
ligation products were PCP, amplified with primer pair
lktCAf/lktCAr and the products were cloned using a commercially
available vector (PCR2.1, invitrogen, Carlsbad, Calif.) according
to manufacturer instructions.
[0099] A product containing an approximately 2.3 kb insert was
selected and proper sequence across the deletion was confirmed by
DNA sequencing and designated pTA.DELTA.lktCA. A kanamycin cassette
derived from pUC4K was placed into the SalI site of pBC
SK-(Stratagene Inc.) to generate pBCKan. The 2.3 kb deleted
leukotoxin insert in pTAAIktCA was transferred into pBCKan by
digestion with EcoRI and ligation into the unique EcoRI site to
form pBCKan.DELTA.lktCA This product was amplified by PCR using
primer pair lktCAdelf (SEQ ID NO:3) and lktRBSr (SEQ ID NO:5) to
replace the native lktC ribosome binding site (RBS) with a
consensus RBS (FIG. 1). The product was digested with Muni and
ligated onto itself to form pBCKan.DELTA.lktCArbs. Proper sequence
adjacent to the deletion was confirmed by DNA sequencing. Finally
the pBC plasmid backbone of both pBCKan.DELTA.lktCA and
pBCKan.DELTA.lktCArbs was replaced with the temperature-sensitive
plasmid origin of replication from pCT109GA189 (Briggs and Tatum,
2005) by ligating BssHII-digested preparations of each to generate
pCT109GA189Kan.DELTA.lktCA and pCT109GA89Kan.DELTA.lktCArbs.
[0100] Electrocompetent M. haemolytica serotype AI D153 cella
(virulent parental strain were transformed with pCT109GA189Kan
lktCA and pCT109GA189Kan.DELTA.lktCArbs by previously described
methods except unmethylated ligation product was directly
introduced into the competent cells, (Briggs and Tatum, 2005)
Briefly, cells were made electrocompetent by growing them to
logarithmic phase in 100 mi of Columbia broth (Difco Laboratories,
Detroit, Mich.) at 37.degree. C. with gentle shaking. The cells
were pelleted by centrifugation at 5,000 .mu.g and washed in 100 ml
of 272 mM sucrose at 0.degree. C., and the pellet was suspended in
an equal volume of 272 mM sucrose at 0.degree. C. After
electroporation, cells recovered overnight in 10 ml Columbia broth
at 30.degree. C. Growth (50 .mu.l) was spread onto Columbia agar
plates containing 50 .mu.g/ml kanamycin, which were then incubated
36 hours at 30.degree. C. Individual colonies were passed to broth
containing 50 .mu.g/ml kanamycin and incubated overnight at
30.degree. C. Growth (100 .mu.l) was passed again to Columbia agar
plates with kanamycin which were incubated overnight at 39.degree.
C.
[0101] Individual colonies were passed to trypticase soy agar (TSA)
plates containing 5% defibrinated sheep blood (BA plates, incubated
overnight at 39.degree. C.) and to Columbia broth without selection
(incubated overnight at 30.degree. C.). Growth in broth was
streaked for isolation on BA plates and passed again in broth at
30.degree. C. Non-hemolytic colonies which were kanamycin-sensitive
were detected on BA plates after 1 to 3 passages without selection.
Representative colonies from each recipient strain and replacement
plasmid were selected for further study.
[0102] Because the temperature-sensitive plasmid origin functions
poorly in E. coli cloning hosts, these final ligation products were
introduced directly into M. haemolytica. Prior cloning steps used
E. coil DH11S (Life Technologies, Rockville, Md.) as the cloning
host.
[0103] Non-hemolytic mutants were grown in Columbia broth at
37.degree. C. for 3 hours and harvested in late logarithmic growth.
Supernatants were dotted onto nitrocellulose along with
supernatants from the wild-type parent and a leukotoxin-negative
isogenic mutant. After appropriate blocking and washing, the blot
was probed with monoclonal anti-leukotoxin antibody 2C9-1E8
(neutralizing antibody produced by NADC, Ames, Iowa), Mutant
products containing the native ribosome binding site were found to
express low levels of protein reactive to monoclonal antibody, less
than that produced by the wild-type parent strain. Products which
contained the new ribosome binding site produced much higher levels
of reactive protein. Supernatants of two products expressing high
levels of leukotoxin were concentrated I5-fold on a 10,000 MW
filter (Centriprep, Amicon). The concentrates (1.5 .mu.l) were
subjected to SDS-PAGE, blotted to nitrocellulose, and probed with
antibody 2C9-1E8. Western blot analysis indicated a new protein
reactive with neutralizing anti-leukotoxin monoclonal antibody at
an apparent molecular weight consistent with the 27 kDa predicted
protein (truncated LktA) product. These representative mutants and
single-crossover controls were analyzed by PCR to demonstrate the
absence of temperature-sensitive origin and kanamycin-resistance
cassette (Step G). The mutant M. haemolytica serotype A1 was
designated as D153.DELTA.lktCA4-707, which refers to the amino acid
positions in LktC and LktA respectively where the deleted region
begins and ends. Gene insertion was characterized by PCR
amplification using LktCAf (SEQ ID NO:1) and LktCAr (SEQ ID NO:2)
primers, which flank the deletion site. As indicated by the gel
image, PCR amplification yielded the expected 2.3 kb for truncated
LktCA, and 5.0 :kb for the wildtype bacterium (FIG. 4A). Finally,
PCR performed with primers (SEQ ID NOs: 1 & 2) flanking ts ori
and kanamycin resistance genes confirmed those elements were no
longer present in the final LktCA mutant for Master Seed (MS). Five
microliters of the concentrated culture supernatant as run on a
SDS-PAGE system, blotted onto PVDF membrane and probed using mouse
anti-LktA, neutralizing antibody 2C9-IE8 (1:1000) as primary
antibody. Goat anti-mouse IgG (1:4000) coupled with alkaline
phosphatase was used as secondary antibody and developed in a
substrate solution containing NBT/BCIP for I-5 min (FIG. 4B). The
lack of functional acylase prevents the activation of LktA, and
furthermore, the N-terminal deletion of LktA prevents it from
forming pores on host animal neutrophils or macrophages.
Example 2
Efficacy of Attenuated M. haemolytica in Calves
[0104] Calves were randomly assigned to one of three groups, each
receiving either 10.sup.6 or 10.sup.7 CFU of the MHA A1+A6 vaccine,
or the control RPMI (diluent). Lyophilized Mannheimia haemolytica
(MH) serotypes A1 and A6 were resuspended and administered
intranasally, I mL to each nostril, of nine calves, aged 5-6 weeks.
The calves were observed for feed intake and rectal temperatures
taken morning and evening for 3 days post vaccination. Nasal
colonization of M. haemolytica A1 and A6 following vaccination was
analyzed by RT-QPCR. (differentiated among M. haemolytica A1 and A6
throughout the study). Vaccines were plated on TSA for exact CFU/ml
count on each vaccine the following day.
[0105] Challenge. A fresh glycerol stock of virulent MH A1 was
grown O/N in BHI medium, plated (TSA) the next day and incubated at
37.degree. C. The following day, plates were scraped and diluted
into RPMI medium supplemented with 2% inactivated fetal bovine
serum. The inoculum was grown at 37.degree. C./200 rpm until
desired O.D.sub.600 was achieved, and the culture was diluted to
the desired CFU/challenge dose and dilution plated to enumerate the
exact CFU/ml the following day. The remaining inoculum was
immediately dilution plated in the lab. Calves were challenged on
DAY via trans-tracheal administration of 2.4.times.10.sup.9 CPU in
20 ml RPMI, chased with 60 ml RPMI. The calves were monitored for
change in behavior including lethargy, coughing, nasal discharge
and scored as shown in Table 3. Rectal. temperatures were monitored
for calves showing clinical signs. The lungs were scored for
pneumonic lesions and recorded as % lesion on each lobe, and lung
tissue was also collected for histopathology. Swabs were taken from
lung lesions and trachea to recover the challenge organism. Table 1
presents the study schedule.
TABLE-US-00001 TABLE 1 Study schedule Age Day Event 5-6 0 Day
0-Bleed, Swab and vaccinate intra-nasally weeks 7 7 days post
vax-Bleed and swab old 14 14 days post vax-Bleed and swab 21 21
days post vax-Bleed and swab 22 22 days post vax-Bleed, swab &
Challenge with M. haemolytica A1 22-29 Observe clinical signs
starting 8/7, euthanize any calves if necessary. Euthanize and
necropsy all on 8/13 *Calves were observed for feed intake and
rectal temperatures (morning/evening) for 3 days, post
vaccination.
Samples from each calf were tested using whole cell, Lkt ELISA and
RT-QPCR.
TABLE-US-00002 TABLE 2 Clinical signs criteria 0 = Normal 1 =
Depression, Anorexia, Cough, Nasal Discharge, Dyspnea 2 = Severely
Depressed, Unable to Rise or Walk, Euthanized for Humane Reasons 3
= Dead On Arrival (DOA)
[0106] Results. Three days post challenge one of the control calves
showed severe signs of pneumonia and was euthanized (36.92% typical
M. haemolytica lesions). The remaining 8 calves were euthanized on
day 6 and their percent lung involvement is described in Table 3.
The results clearly indicate that the vaccine affords protection
when administered intranasally. As indicated in table 4 intranasal
vaccination of M. haemolytica A1/A6 combo significantly reduced
(62.0% and 76.7% for 6 log and 7 log group respectively) the lung
lesions when compared to sham. Furthermore, histopathological
analysis clearly indicated typical necrotizing bronchopneumonia
characteristic of M. haemolytica.
TABLE-US-00003 TABLE 4 Average % reduction in Average lung lesion
Actual vaccine dose Lung lung compared Animal # A1/A6 CFU/animal
lesion (%) lesion (%) to sham 125 1.19 .times. 10.sup.6/9.2 .times.
10.sup.5 24.03* 176 1.19 .times. 10.sup.6/9.2 .times. 10.sup.5 0.0
188 1.19 .times. 10.sup.6/9.2 .times. 10.sup.5 6.40 10.43 62.0 179
1.19 .times. 10.sup.7/9.2 .times. 10.sup.6 0.87 185 1.19 .times.
10.sup.7/9.2 .times. 10.sup.6 1.837 189 1.19 .times. 10.sup.7/9.2
.times. 10.sup.6 14.91* 6.48 76.7 122 Sham 8.85 177 Sham 37.75 182
Sham 36.92 27.84 *The lesions (gross pathology) were due to typical
Mycoplasma bovis chronic infection
Example 3
Development of RT-QPCR Method for Distinguishing Between A1 /A6
Serotypes
[0107] The efficacy of intranasal colonization of M. haemolytica
A1/A6 was followed during the course of experiment by a novel QPCR
method. Briefly, the genomes of above-described A1 and A6 serotype
bacteria were compared against one A1 and two A2 genomes available
in GenBank. The comparison revealed 63 genes specific for A1 (D153)
and 42 genes specific for A6 (D174). Out of these 105 genes we
picked a S6 family IgA-specific metalloendopeptidase (SEQ ID NO:14)
specific for A1 and BCCT family betaine/camitinelcholine
transporter gene (SEQ ID NO:12) specific for A6 respectively for
differential real time PCR. These gene sequences were amplified by
using gene specific primers, sequenced by standard Sanger method
and verified. Next, we designed real time PCR primers and tagged
the probes with two different dyes (A1-5'6 FAM/ZEN/3 and
A6-5'Cy5/3'IBRQ) within each gene. To verify the efficacy our assay
method we picked M. haemolytica colonies from nasal swabs obtained
from calves maintained in our facilities 7 days post vaccination.
The individual colonies were amplified by multiplex real time
colony PCR using QuantiTect Probe PCR kit mastermix (Qiagen)
following the manufacturer's instruction in a MX3000P qPCR machine
(Stratagen). A1 and A6 colonies verified by serotyping were used as
positive controls for multiplex real time quantitative PCR
(RT-QPCR). The et values were set at machine default setting and
each colony verified by multiplex real time PCR was confirmed by
leukotoxin (LktA) specific PCR. The RT-QPCR results 7 days post
vaccination indicated a preferential colonization of A1 over A6
(Table 5), Which was further confirmed by leukotoxin gene specific
deletion PCR (Table 6). But 14 and 21 days post vaccination
indicated essentially exclusive colonization of A1 (Tables 7 &
8).
TABLE-US-00004 TABLE 5 RT-QPCR results for nasal swabs from D7 Post
Vaccination ID A1 A6 .DELTA.Lkt 151-1 17 11 + 151-2 15 - + 151-3 16
- + 151-4 17 - + 151-5 15 - + 154-1 - - 154-2 - 39 154-3 - - 154-4
- - 154-5 - 22 157-1 15 - + 157-2 22 - + 157-3 17 - + 157-4 15 33 +
157-5 16 - + 160-1 18 13 + 160-2 - 12 + 160-3 - 12 + 160-4 - 12 +
160-5 - 11 + 178-1 - - 178-2 - - 178-3 - - 178-4 - 24 178-5 - 31
181-1 15 15 + 181-2 17 - + 181-3 - 13 + 181-4 17 - + 181-5 15 - +
183-1 16 12 + 183-2 - 35 183-3 17 - + 183-4 16 - + 183-5 - 17 +
186-1 - 42 186-2 - 43 186-3 - - 186-4 - - 186-5 - 20 190-1 - -
190-2 - - 190-3 - 10 190-4 - - 190-5 - - 193-1 15 38 + 193-2 15 - +
193-3 - 36 193-4 16 20 + 193-5 - - A1 mut. Vx 15 - + A6 mut. Vx -
11 + Neg - -
TABLE-US-00005 TABLE 6 PCR results for nasal swabs from D7 Post
Vaccination ID/colony A1 A6 Lkt .DELTA. ~2300 bp 122-1 - - 122-2 -
- 122-3 - - 122-4 - - 122-5 - - 125-1 16 - + Y 125-2 17 - + Y 125-3
17 - + Y 125-4 16 - + Y 125-5 17 - + Y 176-1 17 - + Y 176-2 17 - +
Y 176-3 16 - + Y 176-4 16 - + Y 176-5 16 - + Y 177-1 - - 177-2 - -
177-3 - - 177-4 - - 177-5 - - 179-1 17 - + Y 179-2 16 - + Y 179-3 -
- 179-4 16 - + Y 179-5 29 - + Y 182-1 - - 182-2 - - 182-3 - - 182-4
- - 182-5 - - 185-1 - 15 + Y 185-2 18 - + Y 185-3 16 - + Y 185-4 -
- + Y 185-5 22 - + Y 188-1 - - 188-2 - - 188-3 - - 188-4 - - 188-5
- - 189-1 16 - + Y 189-2 16 - + Y 189-3 21 - + Y 189-4 16 - + Y
189-5 17 - + Neg - -
TABLE-US-00006 TABLE 7 PCR results for nasal swabs from D14 Post
Vaccination ID-colony # A1 A6 Lkt .DELTA. PCR Lkt .DELTA. 122-1
(Con. 0 0 Neg 122-2 (Con. 0 0 Neg 122-3 (Con. 0 0 Neg 125-1 (6 log)
15 0 Pos Y 125-2 (6 log) 16 0 Pos Y 125-3 (6 log) 16 0 Pos Y 176-1
(6 log) 0 0 Neg 176-2 (6 log) 0 0 Neg 176-3 (6 log) 0 0 Neg 177-1
(Con. 0 0 Neg 177-2 (Con. 0 0 Neg 177-3 (Con. 0 0 Neg 179-1 (7 log)
0 0 Neg 179-2 (7 log) 0 0 Neg 179-3 (7 log) 0 0 Neg 182-1 (Con.) 0
0 Neg 182-2 (Con.) 0 0 Neg 182-3 (Con.) 0 0 Neg 185-1 (7 log) 0 0
Neg 185-2 (7 log) 0 0 Neg 185-3 (7 log) 0 0 Neg 188-1 (6 log) 0 0
Neg 188-2 (6 log) 0 0 Neg 188-3 (6 log) 0 0 Neg 189-1 (7 log) 15 0
Pos Y 189-2 (7 log) 15 0 Pos Y 189-3 (7 log) 15 0 Pos Y A1 Mutant
Pos 15 0 Pos Y A6 Mutant Pos 0 16 Pos Y Neg Con. 0 0 Neg
TABLE-US-00007 TABLE 8 PCR results for nasal swabs from D21 Post
Vaccination ID-colony # A1 A6 Lkt .DELTA. PCR Lkt .DELTA. 122-1
(Con.) 0 0 .DELTA. 122-2 (Con.) 0 0 122-3 (Con.) 0 0 125-1 (6 log
14 0 + Y 125-2 (6 log 15 0 + Y 125-3 (6 log 15 0 + Y 176-1 (6 log
15 0 + Y 176-2 (6 log 15 0 + Y 176-3 (6 log 15 0 + Y 177-1 (Con.) 0
0 177-2 (Con.) 0 0 177-3 (Con.) 0 0 179-1 (7 log 0 0 179-2 (7 log 0
0 179-3 (7 log 0 0 182-1 (Con.) 0 0 182-2 (Con.) 0 0 182-3 (Con.) 0
0 185-1 (7 log) 15 0 + Y 185-2 (7 log) 14 0 + Y 185-3 (7 log) 15 0
+ Y 188-1 (6 log) 14 0 + Y 188-2 (6 log) 15 0 + Y 188-3 (6 log) 14
0 + Y 189-1 (7 log) 16 0 + Y 189-2 (7 log) 17 0 + Y 189-3 (7 log)
15 0 + Y A1 Mutant Pos 15 0 + Y A6 Mutant Pos 0 16 + Y Neg Control
0 0 neg Pre Challenge A1 Wt 15 0 + WT Post Challenge A1 Wt 16 0 +
WT
Example 3
Intranasal Vaccination of Calves Using Mannheimia haemolytica A1
& A6 Vaccines Followed By Virulent Challenge
[0108] Fifteen calves, 4 weeks of age and housed in 3 different
pens/5 calves per pen, were randomly assigned to one of the two
treatment groups. Calves were vaccinated intranasally with modified
live Mannheimia haemolytica serotypes A1 and A6 (reconstituted from
lyophilized, Table 9), and intranasal colonization of A1 and A6 was
monitored by real time PCR. Calves were finally challenged with
virulent M. haemolytica A6 (wild type) to determine vaccine
efficacy.
TABLE-US-00008 TABLE 9 Treatment Groups. Total Dose/CFU Group
Treatment per animal Route/volume Calf Id # 1 M. haemolytica A1 +
A6 10.sup.7 (1.43 .times. 10.sup.6 + Intranasal 1 ml 2, 4, 6 8, 10
8.63 .times. 10.sup.5)* per nostril 2 M. haemolytica A1 + A6
10.sup.8 (1.43 .times. 10.sup.7 + Intranasal 1 ml 1, 3, 5, 7, 9
8.63 .times. 10.sup.6)* per nostril 3 Control-Lyophilized control
Intranasal 1 ml 162, 166, 170, RPMI + stabilizer per nostril 174,
175 *Actual CFU/ml based on plate count
[0109] Vaccination, Lyophilized cultures of M. haemolytica A1 and
A6 were enumerated from a batch stored at 4.degree. C. On
vaccination day, the vaccines were diluted in. RPMI (colorless) to
required CFU/ml for each isolate. Similarly, the sham vaccine
(lyophilized RPMI in stabilizer) was diluted in RPMI. The vaccines
were plated on TSA to determine the exact CFU/ml count on each
vaccine the following day. The vaccines were mixed and administered
1 ml/nostril using a repeat syringe attached with a cannula
according to the dose in Table 9. The control group was vaccinated
first, followed by the lowest to highest log group. Following
vaccination, the samples were collected as described in Table 10,
and the calves were observed for feed intake and rectal
temperatures taken morning and evening for 3 days post vaccination.
Nasal colonization of M. haemolytica A1 and A6 following
vaccination was analyzed by Q-PCR as described above.
[0110] M. haemolytica A6 challenge culture. A fresh glycerol stock
of M. haemolytica A6 was grown O/N in BM medium, plated (TSA) the
next day and incubated at 37.degree. C. The following day, plates
were scraped and diluted into RPMI medium supplemented with 2%
inactivated fetal bovine serum. The inoculum was grown at
37.degree. C./200 rpm until desired OD.sub.600 was achieved. The
culture was diluted to desired CFU/challenge dose and dilution
plated to enumerate the exact CFU/ml the following day. The
inoculum was transported on ice and kept on ice during challenge,
and administered trans-tracheally using a 14G.times.1 inch needle.
The dose was 1.09.times.10.sup.9 CFU/animal in 20 ml RPMI, chased
with 60 ml RPMI. Once completed, the remaining inoculum was
immediately dilution plated. The calves were monitored for behavior
changes including lethargy, coughing, and nasal discharge and
scored as shown in Table 11. Rectal temperatures were monitored for
calves showing clinical signs. The lungs were scored for pneumonic
lesions and recorded as % lesion on each lobe, and tissues were
collected for histopathology. Swabs were also taken from lungs
(lesions) and trachea to recover the challenge organism.
TABLE-US-00009 TABLE 10 Study Schedule. Age Date Event 4 weeks old
0 Day 0-Bleed, Swab and vaccinate intra-nasally 7 days post vax 7
days post vax-Bleed and swab 15 days post vax 15 days post
vax-Bleed and swab & Challenge with M. haemolytica 15 to 20
days post Observe clinical signs starting day 15; vax euthanized
any calves when necessary. Euthanized and necropsy all on day 20
*Feed intake (daily) and rectal temperatures (twice daily) were
monitored or 3 days post vaccination.
TABLE-US-00010 TABLE 11 Clinical signs. Criteria for Post Challenge
Observations 0 = Normal 1 = Depression, Anorexia, Cough, Nasal
Discharge, Dyspnea 2 = Severely Depressed, Unable to Rise or Walk,
Euthanized for Humane Reasons 3 = Dead On Arrival (DOA)
[0111] Results. Two days post challenge calf# 5 and 174 showed
severe signs of pneumonia and were euthanized. Calf #7 died on day
3, post challenge. The remaining 12 calves were euthanized on day 5
and their % lung involvement is described in Table 4. The results
indicate that 80% of vaccinates were protected by the modified live
M. haemolytica Al! A6 vaccine. From the 7 log group, three (1, 3
and 9) animals were protected while the other two animals (5, 7)
had significantly large lesions compared to controls. The large
lesions could have been caused by an existing Mannheimia,
mycoplasma or viral infection, which had been exacerbated by
challenge. Overall, 80% of vaccinates (1, 2, 3, 4, 6, 8, 9 and 10)
had significantly (89.55% reduction) reduced lung lesion as
compared to control, and histopathological analysis indicated
typical necrotizing bronchopneumonia in the control animals.
TABLE-US-00011 TABLE 12 Dosage groups. Actual A1/A6 Lung Average
Average % reduction in vaccine dose lesion lung lesion lung lesion
compared to Group Animal # CPU/animal (%) (%) sham vaccine 10.sup.7
2 1.43 .times. 10.sup.6/8.63 .times. 10.sup.5 0.0 4 1.43 .times.
10.sup.6/8.63 .times. 10.sup.5 8.67 6 1.43 .times. 10.sup.6/8.63
.times. 10.sup.5 5.92 8 1.43 .times. 10.sup.6/8.63 .times. 10.sup.5
4.83 10 1.43 .times. 10.sup.6/8.63 .times. 10.sup.5 0.0 3.88 85.04
10.sup.8 1 1.43 .times. 10.sup.7/8.63 .times. 10.sup.6 0.0 3 1.43
.times. 10.sup.7/8.63 .times. 10.sup.6 0.0 5 1.43 .times.
10.sup.7/8.63 .times. 10.sup.6 41.58 7 1.43 .times. 10.sup.7/8.63
.times. 10.sup.6 64.47 9 1.43 .times. 10.sup.7/8.63 .times.
10.sup.6 2.295 21.66 14.47 162 Sham 37.11 166 Sham 29.82 170 Sham
11.235 174 Sham 25.54 175 Sham 25.97 25.93
[0112] The efficacy of intranasal colonization of M. haemolytica
A1/A6 was followed during the course of experiment by
above-described QPCR methods. Results for 7 and 15 days
post-vaccination indicated vaccinates had a preferential
colonization of A1 over A6 which was further confirmed by
leukotoxin gene specific deletion PCR (Tables 13 & 14).
TABLE-US-00012 TABLE 13 Day 7 Post Vaccination Sample # Animal #
FAM MHA1 MHA1? CY5 MHA6 MHA6? 1 1 No Ct 16.5 + 2 1 No Ct 38.26 + 3
1 No Ct 16.53 + 4 1 No Ct 25 + 5 2 No Ct No Ct 6 2 No Ct No Ct 7 2
No Ct No Ct 8 2 17.01 + No Ct 9 3 No Ct 15.87 + 10 3 25.11 + 20.81
+ 11 3 21.91 + 19.69 + 12 3 22.35 + 21.8 + 13 4 16.52 + No Ct 14 4
17.11 + No Ct 15 4 16.26 + No Ct 16 4 16 + No Ct 17 5 39.07 +
41.17*Plot was bad ~NEG 18 5 15.98 + No Ct 19 5 16.4 + No Ct 20 5
16.44 + No Ct 21 6 17.08 + No Ct 22 6 18.24 + No Ct 23 6 16.8 + No
Ct 24 6 17.94 + No Ct 25 7 17.98 + No Ct 26 7 No Ct 16.34 + 27 7
26.57 + 15.46 + 28 7 16.7 + 17.52 + 29 8 16.7 + No Ct 30 8 16.71 +
No Ct 31 8 16.1 + No Ct 32 8 15.16 + No Ct 33 9 16.32 + No Ct 34 9
17.03 + No Ct 35 9 16.63 + No Ct 36 9 16.04 + No Ct 37 10 No Ct No
Ct 38 10 No Ct No Ct 39 10 No Ct No Ct 40 10 No Ct No Ct 41 162 No
Ct No Ct 42 162 No Ct No Ct 43 162 No Ct No Ct 44 162 No Ct No Ct
45 166 No Ct No Ct 46 166 No Ct No Ct 47 166 No Ct No Ct 48 166 No
Ct No Ct 49 170 No Ct No Ct 50 170 No Ct No Ct 51 170 No Ct No Ct
52 170 No Ct No Ct 53 174 No Ct No Ct 54 174 No Ct No Ct 55 174 No
Ct No Ct 56 174 No Ct No Ct 57 175 No Ct No Ct 58 175 No Ct No Ct
59 175 No Ct No Ct 60 175 No Ct No Ct 61 A1 mut + 16.66 No Ct 62 A6
mut + No Ct 13.85 63 A1 Wt + 15.87 No Ct 64 Neg 40.77 No Ct
TABLE-US-00013 TABLE 14 Day 15 Post Vaccination Animal # FAM MHA1
MHA1? CY5 MHA6 MHA6? Lkt del PCR 1 No Ct 40.53 1 No Ct No Ct 1 No
Ct No Ct 1 No Ct No Ct 1 No Ct No Ct 2 No Ct No Ct 2 No Ct No Ct 2
No Ct No Ct 2 No Ct No Ct 2 No Ct No Ct 3 No Ct 15.1 + Mutant 3 No
Ct 15.08 + Mutant 3 No Ct 15.19 + Mutant 3 No Ct 15.3 + Mutant 3 No
Ct 15.1 + Mutant 4 15.82 No Ct Mutant 4 No Ct No Ct 4 No Ct No Ct 4
No Ct No Ct 4 No Ct No Ct 5 16.13 + No Ct Mutant 5 15.27 + No Ct
Mutant 5 17.03 + No Ct Mutant 5 16.49 + No Ct Mutant 5 18.06 + No
Ct Mutant 6 No Ct No Ct 6 No Ct No Ct 6 No Ct No Ct 6 40.05 No Ct 6
No Ct No Ct 7 No Ct 16.83 + Mutant 7 No Ct No Ct + 7 No Ct 14.92 +
Mutant 7 No Ct 15.21 + Mutant 7 No Ct 16.16 + Mutant 8 No Ct No Ct
8 No Ct No Ct 8 No Ct No Ct 8 No Ct No Ct 8 No Ct No Ct 9 No Ct No
Ct 9 No Ct No Ct 9 No Ct No Ct 9 No Ct No Ct 9 No Ct No Ct 10 15.94
+ No Ct Mutant 10 No Ct + No Ct 10 No Ct + No Ct 10 23.82 + No Ct
Mutant 10 30.04 + No Ct Mutant 162 No Ct No Ct 162 No Ct No Ct 162
No Ct No Ct 162 No Ct No Ct 162 No Ct No Ct 166 No Ct No Ct 166 No
Ct No Ct 166 No Ct No Ct 166 No Ct No Ct 166 No Ct No Ct 170 No Ct
No Ct 170 No Ct No Ct 170 No Ct No Ct 170 No Ct No Ct 170 No Ct No
Ct 174 No Ct No Ct 174 No Ct No Ct 174 No Ct No Ct 174 No Ct No Ct
174 No Ct No Ct 175 16.24 + No Ct Mutant 175 No Ct + No Ct 175
16.54 + No Ct Mutant 175 No Ct + No Ct Mutant 175 23.06 + No Ct
Mutant ********
[0113] Having thus described in detail preferred embodiments of the
present invention, it is to be understood that the invention
defined by the above paragraphs is not to be limited to particular
details set forth in the above description as many apparent
variations thereof are possible without departing from the spirit
or scope of the present invention.
Sequence CWU 1
1
26126DNAArtificial SequencelktCAf primer 1gcattgaatt gatcaactaa
tacttg 26225DNAArtificial SequencelktCAr primer 2caaggtttct
agaaagattt ttcgg 25331DNAArtificial SequencelktCAAdelf primer
3gatcaattga aagctgttga agaaattatc g 31429DNAArtificial
SequencelktCAAdelr primer 4atacaattga ttcataattt gcactcgat
29548DNAArtificial SequencelktRBSr primer 5caacaattga ttcataattt
gcctcctata attattctaa attaggtc 4861068DNAArtificial Sequence5'
deltalktCA PCR fragment 6gcattgaatt gatcaactaa tacttggttt
ttcaagtgag ttgcaatgcc taaaccatca 60ccaaaatagt ttggattatt gattttctcc
cctacaaaat ctagcccttc gtgttttctt 120gccatctcag ccaataccgg
cacatcgcca aaaatagcat caattcgccc attttgcaca 180tctaaaatag
cattttgata agaggcataa gatttcacat tgtactcttt tttctctttt
240gctaaatagt gttggtaagt agtcccattt tgcacaccaa tcgttttcac
cttagcaaaa 300tctgtatctt ttttcgcaat gaaggcagca gagcttggaa
agtaaggctc gctaaataat 360acttgtttct tacgtggttc cgtaataccc
atacctgaaa ttgcagcatc aaattgtttt 420tgttttaggc tttggattaa
gctatcaaaa ggttggctat ggaatgtaca atttgcattc 480atctctttac
agatagcatt tgcaatatcc acatcaaaac cgataatttc tcccttctct
540tcggtcattt caaatggagg atagcttggc tccatcacaa atttgatatc
ttgtgcctgc 600gcagtaacca cacacccgaa taaaagggtc aaaagtgttt
ttttcataaa aagtccctgt 660gttttcatta taaggattac cactttaacg
cagttacttt cttaaaaaaa gtcttctttt 720cataaagttt gttttatgtc
atacaaacac atcaaattga gatgtagttt ctcaatcctc 780ttgattcctc
tatctcaaaa aaacaaccca aaagaaaaaa gaaaagtata tgttacatta
840atattacaat gtaattattt tgtttaattt ccctacattt tgtataactt
taaaacactc 900ctttttctct tctgattata taaaagacaa aaaatacaat
ttaagctaca aaaaacaaca 960aaaaacaaca aaaaacacga caataagatc
gagtaatgat tatattatgt tataattttt 1020gacctaattt agaataatta
tcgagtccaa attatgaatc aattgtat 106871295DNAArtificial Sequence3'
deltalktCA PCR fragment 7caattgaaag ctgttgaaga aattatcggt
acatcacata acgatatctt taaaggtagt 60aagttcaatg atgcctttaa cggtggtgat
ggtgtcgata ctattgacgg taacgacggc 120aatgaccgct tatttggtgg
taaaggcgat gatattctcg atggtggaaa tggtgatgat 180tttatcgatg
gcggtaaagg caacgaccta ttacacggtg gcaagggcga tgatattttc
240gttcaccgta aaggcgatgg taatgatatt attaccgatt ctgacggcaa
tgataaatta 300tcattctctg attcgaactt aaaagattta acatttgaaa
aagttaaaca taatcttgtc 360atcacgaata gcaaaaaaga gaaagtgacc
attcaaaact ggttccgaga ggctgatttt 420gctaaagaag tgcctaatta
taaagcaact aaagatgaga aaatcgaaga aatcatcggt 480caaaatggcg
agcggatcac ctcaaagcaa gttgatgatc ttatcgcaaa aggtaacggc
540aaaattaccc aagatgagct atcaaaagtt gttgataact atgaattgct
caaacatagc 600aaaaatgtga caaacagctt agataagtta atctcatctg
taagtgcatt tacctcgtct 660aatgattcga gaaatgtatt agtggctcca
acttcaatgt tggatcaaag tttatcttct 720cttcaatttg ctagagcagc
ttaattttta atgattggca actctatatt gtttcacaca 780ttatagagtt
gccgttttat tttataaaag gagacaatat ggaagctaac catcaaagga
840atgatcttgg tttagttgcc ctcactatgt tggcacaata ccataatatt
tcgcttaatc 900cggaagaaat aaaacataaa tttgatcttg acggaaaagg
gctttcttta actgcttggc 960ttttagctgc aaaatcgtta gcgttgaaag
cgaaacacat taaaaaagag atttcccgct 1020tacacttggt gaatttaccg
gcattagttt ggcaagataa cggtaaacat tttttattgg 1080taaaagtgga
taccgataat aaccgctatt taacttacaa tttggaacaa gatgctccac
1140aaattctgtc acaagacgaa tttgaagcct gctatcaagg gcagttaatt
ttggtcacgt 1200ccagagcttc cgtagtaggt caattagcaa agttcgattt
cacctggttt attccggcgg 1260tgatcaaata ccgaaaaatc tttctagaaa ccttg
1295827DNAArtificial SequenceBCCT FAMILY-BETAINE-CARNITINE-CHOLINE
Transporter forward primer 8atgttattcg ccgccggaat ggggatc
27925DNAArtificial SequenceBCCT FAMILY-BETAINE-CARNITINE-CHOLINE
Transporter reverse primer 9acctgcatca ccccaaagcc aagtg
251026DNAArtificial SequenceIGA SPECIFIC SERINE
METALLO-ENDOPEPTIDASE forward primer 10atgaagacca aaacatttac tcgttc
261125DNAArtificial SequenceIGA SPECIFIC SERINE
METALLO-ENDOPEPTIDASE reverse primer 11agcgcttgtg tccctgaacc agcac
25122007DNAP. multocida 12ttggatttaa tcaaaaaatt aaacacagga
agtaccttta gggtaccgat tttcctaccg 60agtttactct ttgtcagctt tgttgccgtt
ttctgtatca tctttccaca gcaagcacaa 120acctcacttg ataccatcaa
aaatagtctc ttccaacatt ttagctggtt ctatattttt 180gcaggctcta
tctttttcct gtttctaatt tttctctctt tcagccgatt gggtgatatt
240aaattagggg cagataccga tgagcctgaa tttggttttg gctcttggat
tgcgatgtta 300ttcgccgccg gaatggggat cgggttaatg tattttgggg
tagcagaacc tattttgcat 360taccttaaac ccgtccaaca aaatttaact
gagccggagc gtatgaaaga agcgatgatg 420acaacgttct atcattgggg
tattcacgct tgggcaattt atggtgtgat tgccttagct 480cttgcttatt
ttggcttcag atataagtta gcactcacta ttcgttccgg attttatccc
540ttactaaaac atcgtatttc aggcttctgg gggcatttaa ttgatattat
tgccctttgt 600agcacgattt tcggtttaac gactacactt ggctttgggg
tgatgcaggt cagtgctggc 660tttaacaatc taggtttaat tgaacagagc
aattttactg ttcttgcgat tatcgtaaca 720gtagcaatgg ctcttgccgt
gttatctgcc gtttcgggcg taggcaaagg ggttaaaatc 780ttaagtgaaa
tcaatctcac attagccgga ttgctactta tttttgtgat aatcaccggc
840ccaactctat tacttttctc aagcttcacc gaaaatttag gctattattt
tagctcgctg 900cttgagatga gtttccgtac cttcgcttat gaaccggaac
atcaaggctg gctaagcggc 960tggacggtcc tttattgggc atggtgggca
tcttgggcgc catttgttgg tttgtttatt 1020gccaagatct ctaaaggcag
aaccattcgt gaatttattt taggggtgct atttgttcca 1080tcgctgttta
acattttatg gatgaccagc ttcggcagct ctgccatttg gttcgatcaa
1140caaactgccg gtgctttagc tgaagtcagc ggcaataccg aacaactgtt
atttaccttt 1200tttgagcaat taccgtttgg ctctattgcc tctttcgttg
ccgtcattgt tatcagtatt 1260ttctttatca cctctgccga ctcggggatt
tttgttctca acagcattgc ttcacaaggc 1320gaagaaaatg caccgaaatg
gcaaagcgtg ctttggggag cattattagc catcttagcg 1380ttatcactac
tctattcggg tggcttggct tctctgcaaa caatgacact gattatcgcc
1440ttaccattta ccttcattat gctgattctc tgtatcggct tatggaaagg
attaatggta 1500gataaccaat acttcaacaa aaaattctcg caaggtagcc
aacattgggc gggtaaagat 1560tggaaacaac gcttggagaa aatcatcaac
ccaagcaata agcaagatgt ccgtcacttc 1620tttattaaag ttgccagacc
agcattttta gaacttatcg aggaatttga aagctatggc 1680ttaatcgcta
aaatgaattt caccaacgaa caaaacccga aattagagtt tgaagtggtg
1740aaagaaaatt tacgcaattt catttacggc attgaaagtg tgccacggga
attatcggat 1800ttggtggtag gtgacgacaa cctaccgaac attgagcaaa
ataccattta cgagccgatt 1860acttatttct tagacgggcg gaaaggttat
gatgtgcaat atatgaccaa agaagagttg 1920attgccgacg tgctgcaaca
gtatgaacgc tttatcaatt tagcgatgga caactcgcac 1980gacttaatga
cggctgattt caatcac 200713669PRTP. multocida 13Leu Asp Leu Ile Lys
Lys Leu Asn Thr Gly Ser Thr Phe Arg Val Pro1 5 10 15Ile Phe Leu Pro
Ser Leu Leu Phe Val Ser Phe Val Ala Val Phe Cys 20 25 30Ile Ile Phe
Pro Gln Gln Ala Gln Thr Ser Leu Asp Thr Ile Lys Asn 35 40 45Ser Leu
Phe Gln His Phe Ser Trp Phe Tyr Ile Phe Ala Gly Ser Ile 50 55 60Phe
Phe Leu Phe Leu Ile Phe Leu Ser Phe Ser Arg Leu Gly Asp Ile65 70 75
80Lys Leu Gly Ala Asp Thr Asp Glu Pro Glu Phe Gly Phe Gly Ser Trp
85 90 95Ile Ala Met Leu Phe Ala Ala Gly Met Gly Ile Gly Leu Met Tyr
Phe 100 105 110Gly Val Ala Glu Pro Ile Leu His Tyr Leu Lys Pro Val
Gln Gln Asn 115 120 125Leu Thr Glu Pro Glu Arg Met Lys Glu Ala Met
Met Thr Thr Phe Tyr 130 135 140His Trp Gly Ile His Ala Trp Ala Ile
Tyr Gly Val Ile Ala Leu Ala145 150 155 160Leu Ala Tyr Phe Gly Phe
Arg Tyr Lys Leu Ala Leu Thr Ile Arg Ser 165 170 175Gly Phe Tyr Pro
Leu Leu Lys His Arg Ile Ser Gly Phe Trp Gly His 180 185 190Leu Ile
Asp Ile Ile Ala Leu Cys Ser Thr Ile Phe Gly Leu Thr Thr 195 200
205Thr Leu Gly Phe Gly Val Met Gln Val Ser Ala Gly Phe Asn Asn Leu
210 215 220Gly Leu Ile Glu Gln Ser Asn Phe Thr Val Leu Ala Ile Ile
Val Thr225 230 235 240Val Ala Met Ala Leu Ala Val Leu Ser Ala Val
Ser Gly Val Gly Lys 245 250 255Gly Val Lys Ile Leu Ser Glu Ile Asn
Leu Thr Leu Ala Gly Leu Leu 260 265 270Leu Ile Phe Val Ile Ile Thr
Gly Pro Thr Leu Leu Leu Phe Ser Ser 275 280 285Phe Thr Glu Asn Leu
Gly Tyr Tyr Phe Ser Ser Leu Leu Glu Met Ser 290 295 300Phe Arg Thr
Phe Ala Tyr Glu Pro Glu His Gln Gly Trp Leu Ser Gly305 310 315
320Trp Thr Val Leu Tyr Trp Ala Trp Trp Ala Ser Trp Ala Pro Phe Val
325 330 335Gly Leu Phe Ile Ala Lys Ile Ser Lys Gly Arg Thr Ile Arg
Glu Phe 340 345 350Ile Leu Gly Val Leu Phe Val Pro Ser Leu Phe Asn
Ile Leu Trp Met 355 360 365Thr Ser Phe Gly Ser Ser Ala Ile Trp Phe
Asp Gln Gln Thr Ala Gly 370 375 380Ala Leu Ala Glu Val Ser Gly Asn
Thr Glu Gln Leu Leu Phe Thr Phe385 390 395 400Phe Glu Gln Leu Pro
Phe Gly Ser Ile Ala Ser Phe Val Ala Val Ile 405 410 415Val Ile Ser
Ile Phe Phe Ile Thr Ser Ala Asp Ser Gly Ile Phe Val 420 425 430Leu
Asn Ser Ile Ala Ser Gln Gly Glu Glu Asn Ala Pro Lys Trp Gln 435 440
445Ser Val Leu Trp Gly Ala Leu Leu Ala Ile Leu Ala Leu Ser Leu Leu
450 455 460Tyr Ser Gly Gly Leu Ala Ser Leu Gln Thr Met Thr Leu Ile
Ile Ala465 470 475 480Leu Pro Phe Thr Phe Ile Met Leu Ile Leu Cys
Ile Gly Leu Trp Lys 485 490 495Gly Leu Met Val Asp Asn Gln Tyr Phe
Asn Lys Lys Phe Ser Gln Gly 500 505 510Ser Gln His Trp Ala Gly Lys
Asp Trp Lys Gln Arg Leu Glu Lys Ile 515 520 525Ile Asn Pro Ser Asn
Lys Gln Asp Val Arg His Phe Phe Ile Lys Val 530 535 540Ala Arg Pro
Ala Phe Leu Glu Leu Ile Glu Glu Phe Glu Ser Tyr Gly545 550 555
560Leu Ile Ala Lys Met Asn Phe Thr Asn Glu Gln Asn Pro Lys Leu Glu
565 570 575Phe Glu Val Val Lys Glu Asn Leu Arg Asn Phe Ile Tyr Gly
Ile Glu 580 585 590Ser Val Pro Arg Glu Leu Ser Asp Leu Val Val Gly
Asp Asp Asn Leu 595 600 605Pro Asn Ile Glu Gln Asn Thr Ile Tyr Glu
Pro Ile Thr Tyr Phe Leu 610 615 620Asp Gly Arg Lys Gly Tyr Asp Val
Gln Tyr Met Thr Lys Glu Glu Leu625 630 635 640Ile Ala Asp Val Leu
Gln Gln Tyr Glu Arg Phe Ile Asn Leu Ala Met 645 650 655Asp Asn Ser
His Asp Leu Met Thr Ala Asp Phe Asn His 660 665144017DNAP.
multocida 14atgaagacca aaacatttac tcgttcttat cttgcttctt ttgtaacaat
cgtattaagt 60ttacctgctg tagcatctgt tgtacgtaat gatgtggact atcaatactt
ccgcgatttt 120gccgaaaata aaggaccatt ttcagttggt tcaatgaata
ttgatattaa agacaacaat 180ggacaacttg taggcacgat gcttcataat
ttaccaatgg ttgattttag tgctatggta 240agaggtggat attctacttt
aattgcacca caatatttag ttagtgttgc acataatact 300ggatataaaa
atgttcaatt tggtgctgca ggttataacc ctgattcaca tcactatact
360tataaaattg ttgaccgcaa tgattatgaa aaggttcaag gagggttgca
cccagactat 420catactcctc gattaaataa attagtaaca gaagttgtgc
ctgccgcagt caccaatgca 480ggtacatcta ttaaacccta cttaaatgaa
gaacgcttcc ctatgtttct tcgtgctggt 540tcagggacac aagcgctaag
aggaaaagaa agtaataaaa caactggaat cgctggtgct 600tatgaatatc
ttactggcgg taccacatta caattatcta aaagctcccc tgatcactgg
660ttagattatt caagtaacct ttatcaagta agctatggac cactttcaac
ctatgcacta 720cctggtgata gtggttcagg ttcttacgcc tatgatatga
acgaaaaacg atgggtatta 780gttggtgtgc tcaatttcta taatggtatg
gataatcaat tcaaccgctc tgcgattatc 840cgtaaagatt tccacgagaa
aaaatttgcc gaagatattg caggaacaat caataatacc 900gtacaaaatg
cacaattcaa ttggactgct caaggtaaat ccagctctct tagtcaatca
960aataatgtgc aaaaactcaa cgttgatcta aaagatagta gcattgcaaa
ccaaaacact 1020tctctgccac aagaaaatca cggtaaaacc attaatttta
atggtaaaga tgcaactatt 1080gtactaaaac aggatattga ccaaggtgca
ggtgcattaa atctgaacgc taatctcact 1140attcgtcctg aaacagacca
aacttggcaa ggtgcaggta ttatcgtcgg taaagataaa 1200aaagtgaatt
ggcaagtaaa aaatccacaa ggcgatcgtt tatctaaact cggggaagga
1260acactctatg taaatggacg tggacagaat cttggcgata tcagtgtagg
tgatggtatt 1320gtaatactta accagcaagc cgatcaccaa ggaagaaaac
aggcctttaa tacagtagga 1380atcgtaagtg gtcgccccac tgttgtgcta
ggtagtgcag atcaagttaa tcccgataat 1440atttactttg gatttcgcgg
aggtcgttta gacctaaacg gtaacagcat cgcctttaaa 1500cgtattcaaa
acagcgataa acatgctcgt attgtaaacc acaatcgcga tcacatttct
1560accttaataa tacaaggcca agatcctctc actagtaatg atcttatatg
gggaaaatgg 1620gcaagtaata gcccagcaga catttacgaa tataccaatc
cttatcaaaa taaacgcaaa 1680gattacttcc gtctgaaagg taattcgaga
gtatattatc caacgaatgc tacaagtaac 1740gatcactggg aatttctttc
cagtaaccgc gagcaagcaa tacagaaaat cctagatgcc 1800aaaaacttaa
gacagcgcta tgacacgttt aatggtttta taggggaaga tgcttccaat
1860aaaactaatg ggatattaaa tgtcgtgttt gatacaaaaa cagaagtaaa
tacagaacaa 1920gataaattaa agaatatcta cacaatgtcg ggaggattta
accttaatgg tgaactcacc 1980cttaaaggtg gtacattgtt gctttctggt
cacccaacgc cacacgctta tgatattaag 2040aataagcatg atgttgtgcg
tgaaaacgat tggcaagaca gccattttac tgctaaaaat 2100atcacggtaa
ataaaatggc acaactctat atcgggagaa atgtcaatga agtaaatagt
2160cactttactg cgactgataa agccaaactc aatttaggat ttattaatcg
ttcaacgcca 2220agttgctatg attctgaata cacaggcact acacattgtg
aagtgcaagc ggtcatttcc 2280gataatattt ttgcaaatct agcaacaacc
gccattaaag gtaatgttaa attacaaaac 2340catagccaat taaatttagg
caaagcaaac ctcactggtt ctgtacaagc tgatcaaaca 2400actcatatca
ctttagcaaa tcacagtcac tggttaaaca atggtacgag ccagattggg
2460catcttacaa tggaaaaagg gtcgatcctt agcctaaacg ataaatttgc
taccacggaa 2520atcccagtcc gattcaacaa gatgatcatc caaggtaatc
taaaaggtaa tggacgaatt 2580aactataccg caaatttagc caagggcgaa
tctgatcatc tccaagttga cggtattgct 2640gaaggaaatt ttgtccttgc
cgttagaaat agcacaactg aagcaaatcc aaaaagctca 2700ttaaacctac
taagcttaaa aaatagcaac caagaaggca ataaagcttc tatttctcta
2760gaaaataatt atgttgatct aggtacttat cgttatgtat tagaaaatcg
taatcacaat 2820taccatttat ttaatccatt aataccaaat tcaacctcta
aagagatgaa tgctacatct 2880gtatcctcta ttccaaaaaa ggaatctgtt
actaatgttc ctactttaga taagaaagaa 2940actgaacaaa atcttactca
actacaaaaa gatttttcag cacaccaatt agaaaatcaa 3000aaagcaaaac
aatctatgat aaatgctcaa tctgagctaa gacgactcaa ttcacaactg
3060aatgtattgc aaaaatatgt gaattctcgt cgcttaggtt actatactca
gcaggcagtt 3120ttagaacaaa ttagcattat tcaaaataaa attaaacaaa
cacaaacaat atttaatgac 3180gctaatgcaa ctgtaaaact cacagatcaa
aagctagaag aagccaaatt agctctaggc 3240tctgtaaacg atcttgtatt
aataaaagcc tctgctccag caatgcaagc aactaatcaa 3300gatacgagta
tgatgaatat tattcaagca gattggataa gccaatacgc taacacagca
3360ctttctgaac tctcggcaca ggctaattct gctctgcaaa tcagtaatag
cttagatcgc 3420caactcttca aacaaagcga taaattcaac gtatggagca
gcgtcgaaca tcagaaaacc 3480gagcataaat cagatttata ccgcccgtat
aaacaacaaa ccaacctgac ccaactgggc 3540atacaaatgc cgatagataa
cggtttaatg tttggagttg cattatctaa aaaccacgct 3600aacgcggaat
ttaacgaggg tgtaaacggt aaatcgaatc tactaatggc aagcctatat
3660ggtaagtggc aatctcaaca aggcactttt atcagccttg atggcagcta
cggtaaagca 3720aaaaaccaac tctacctatt tggtgaaaac cactttaccc
gccgaatttc ctctattggt 3780gctaacattg gacatcaatt tgacctcgca
ggagttcaaa ttcagccaac aataggagca 3840agatactacc atttcagcgg
ccaagactat acactaggag gagcgaaaat cagctcacca 3900aatacccact
ttatgacata tcaagcgggt ctaaaagcta gtaaaacttt tcattggatg
3960actggaaagt tgaaccaagc attacaaccc actatgtgga tgcaagtaac aaacgct
4017151339PRTP. multocida 15Met Lys Thr Lys Thr Phe Thr Arg Ser Tyr
Leu Ala Ser Phe Val Thr1 5 10 15Ile Val Leu Ser Leu Pro Ala Val Ala
Ser Val Val Arg Asn Asp Val 20 25 30Asp Tyr Gln Tyr Phe Arg Asp Phe
Ala Glu Asn Lys Gly Pro Phe Ser 35 40 45Val Gly Ser Met Asn Ile Asp
Ile Lys Asp Asn Asn Gly Gln Leu Val 50 55 60Gly Thr Met Leu His Asn
Leu Pro Met Val Asp Phe Ser Ala Met Val65 70 75 80Arg Gly Gly Tyr
Ser Thr Leu Ile Ala Pro Gln Tyr Leu Val Ser Val 85 90 95Ala His Asn
Thr Gly Tyr Lys Asn Val Gln Phe Gly Ala Ala Gly Tyr 100 105 110Asn
Pro Asp Ser His His Tyr Thr Tyr Lys Ile Val Asp Arg Asn Asp 115 120
125Tyr Glu Lys Val Gln Gly Gly Leu His Pro Asp Tyr His Thr Pro Arg
130 135 140Leu Asn Lys Leu Val Thr Glu Val Val Pro Ala Ala Val Thr
Asn Ala145 150 155 160Gly Thr Ser Ile Lys Pro Tyr Leu Asn Glu Glu
Arg Phe Pro Met Phe 165 170 175Leu Arg Ala Gly Ser Gly Thr Gln Ala
Leu Arg Gly Lys Glu Ser Asn 180 185 190Lys Thr Thr Gly Ile Ala Gly
Ala Tyr Glu Tyr Leu Thr Gly Gly Thr 195 200 205Thr Leu Gln Leu
Ser Lys Ser Ser Pro Asp His Trp Leu Asp Tyr Ser 210 215 220Ser Asn
Leu Tyr Gln Val Ser Tyr Gly Pro Leu Ser Thr Tyr Ala Leu225 230 235
240Pro Gly Asp Ser Gly Ser Gly Ser Tyr Ala Tyr Asp Met Asn Glu Lys
245 250 255Arg Trp Val Leu Val Gly Val Leu Asn Phe Tyr Asn Gly Met
Asp Asn 260 265 270Gln Phe Asn Arg Ser Ala Ile Ile Arg Lys Asp Phe
His Glu Lys Lys 275 280 285Phe Ala Glu Asp Ile Ala Gly Thr Ile Asn
Asn Thr Val Gln Asn Ala 290 295 300Gln Phe Asn Trp Thr Ala Gln Gly
Lys Ser Ser Ser Leu Ser Gln Ser305 310 315 320Asn Asn Val Gln Lys
Leu Asn Val Asp Leu Lys Asp Ser Ser Ile Ala 325 330 335Asn Gln Asn
Thr Ser Leu Pro Gln Glu Asn His Gly Lys Thr Ile Asn 340 345 350Phe
Asn Gly Lys Asp Ala Thr Ile Val Leu Lys Gln Asp Ile Asp Gln 355 360
365Gly Ala Gly Ala Leu Asn Leu Asn Ala Asn Leu Thr Ile Arg Pro Glu
370 375 380Thr Asp Gln Thr Trp Gln Gly Ala Gly Ile Ile Val Gly Lys
Asp Lys385 390 395 400Lys Val Asn Trp Gln Val Lys Asn Pro Gln Gly
Asp Arg Leu Ser Lys 405 410 415Leu Gly Glu Gly Thr Leu Tyr Val Asn
Gly Arg Gly Gln Asn Leu Gly 420 425 430Asp Ile Ser Val Gly Asp Gly
Ile Val Ile Leu Asn Gln Gln Ala Asp 435 440 445His Gln Gly Arg Lys
Gln Ala Phe Asn Thr Val Gly Ile Val Ser Gly 450 455 460Arg Pro Thr
Val Val Leu Gly Ser Ala Asp Gln Val Asn Pro Asp Asn465 470 475
480Ile Tyr Phe Gly Phe Arg Gly Gly Arg Leu Asp Leu Asn Gly Asn Ser
485 490 495Ile Ala Phe Lys Arg Ile Gln Asn Ser Asp Lys His Ala Arg
Ile Val 500 505 510Asn His Asn Arg Asp His Ile Ser Thr Leu Ile Ile
Gln Gly Gln Asp 515 520 525Pro Leu Thr Ser Asn Asp Leu Ile Trp Gly
Lys Trp Ala Ser Asn Ser 530 535 540Pro Ala Asp Ile Tyr Glu Tyr Thr
Asn Pro Tyr Gln Asn Lys Arg Lys545 550 555 560Asp Tyr Phe Arg Leu
Lys Gly Asn Ser Arg Val Tyr Tyr Pro Thr Asn 565 570 575Ala Thr Ser
Asn Asp His Trp Glu Phe Leu Ser Ser Asn Arg Glu Gln 580 585 590Ala
Ile Gln Lys Ile Leu Asp Ala Lys Asn Leu Arg Gln Arg Tyr Asp 595 600
605Thr Phe Asn Gly Phe Ile Gly Glu Asp Ala Ser Asn Lys Thr Asn Gly
610 615 620Ile Leu Asn Val Val Phe Asp Thr Lys Thr Glu Val Asn Thr
Glu Gln625 630 635 640Asp Lys Leu Lys Asn Ile Tyr Thr Met Ser Gly
Gly Phe Asn Leu Asn 645 650 655Gly Glu Leu Thr Leu Lys Gly Gly Thr
Leu Leu Leu Ser Gly His Pro 660 665 670Thr Pro His Ala Tyr Asp Ile
Lys Asn Lys His Asp Val Val Arg Glu 675 680 685Asn Asp Trp Gln Asp
Ser His Phe Thr Ala Lys Asn Ile Thr Val Asn 690 695 700Lys Met Ala
Gln Leu Tyr Ile Gly Arg Asn Val Asn Glu Val Asn Ser705 710 715
720His Phe Thr Ala Thr Asp Lys Ala Lys Leu Asn Leu Gly Phe Ile Asn
725 730 735Arg Ser Thr Pro Ser Cys Tyr Asp Ser Glu Tyr Thr Gly Thr
Thr His 740 745 750Cys Glu Val Gln Ala Val Ile Ser Asp Asn Ile Phe
Ala Asn Leu Ala 755 760 765Thr Thr Ala Ile Lys Gly Asn Val Lys Leu
Gln Asn His Ser Gln Leu 770 775 780Asn Leu Gly Lys Ala Asn Leu Thr
Gly Ser Val Gln Ala Asp Gln Thr785 790 795 800Thr His Ile Thr Leu
Ala Asn His Ser His Trp Leu Asn Asn Gly Thr 805 810 815Ser Gln Ile
Gly His Leu Thr Met Glu Lys Gly Ser Ile Leu Ser Leu 820 825 830Asn
Asp Lys Phe Ala Thr Thr Glu Ile Pro Val Arg Phe Asn Lys Met 835 840
845Ile Ile Gln Gly Asn Leu Lys Gly Asn Gly Arg Ile Asn Tyr Thr Ala
850 855 860Asn Leu Ala Lys Gly Glu Ser Asp His Leu Gln Val Asp Gly
Ile Ala865 870 875 880Glu Gly Asn Phe Val Leu Ala Val Arg Asn Ser
Thr Thr Glu Ala Asn 885 890 895Pro Lys Ser Ser Leu Asn Leu Leu Ser
Leu Lys Asn Ser Asn Gln Glu 900 905 910Gly Asn Lys Ala Ser Ile Ser
Leu Glu Asn Asn Tyr Val Asp Leu Gly 915 920 925Thr Tyr Arg Tyr Val
Leu Glu Asn Arg Asn His Asn Tyr His Leu Phe 930 935 940Asn Pro Leu
Ile Pro Asn Ser Thr Ser Lys Glu Met Asn Ala Thr Ser945 950 955
960Val Ser Ser Ile Pro Lys Lys Glu Ser Val Thr Asn Val Pro Thr Leu
965 970 975Asp Lys Lys Glu Thr Glu Gln Asn Leu Thr Gln Leu Gln Lys
Asp Phe 980 985 990Ser Ala His Gln Leu Glu Asn Gln Lys Ala Lys Gln
Ser Met Ile Asn 995 1000 1005Ala Gln Ser Glu Leu Arg Arg Leu Asn
Ser Gln Leu Asn Val Leu Gln 1010 1015 1020Lys Tyr Val Asn Ser Arg
Arg Leu Gly Tyr Tyr Thr Gln Gln Ala Val1025 1030 1035 1040Leu Glu
Gln Ile Ser Ile Ile Gln Asn Lys Ile Lys Gln Thr Gln Thr 1045 1050
1055Ile Phe Asn Asp Ala Asn Ala Thr Val Lys Leu Thr Asp Gln Lys Leu
1060 1065 1070Glu Glu Ala Lys Leu Ala Leu Gly Ser Val Asn Asp Leu
Val Leu Ile 1075 1080 1085Lys Ala Ser Ala Pro Ala Met Gln Ala Thr
Asn Gln Asp Thr Ser Met 1090 1095 1100Met Asn Ile Ile Gln Ala Asp
Trp Ile Ser Gln Tyr Ala Asn Thr Ala1105 1110 1115 1120Leu Ser Glu
Leu Ser Ala Gln Ala Asn Ser Ala Leu Gln Ile Ser Asn 1125 1130
1135Ser Leu Asp Arg Gln Leu Phe Lys Gln Ser Asp Lys Phe Asn Val Trp
1140 1145 1150Ser Ser Val Glu His Gln Lys Thr Glu His Lys Ser Asp
Leu Tyr Arg 1155 1160 1165Pro Tyr Lys Gln Gln Thr Asn Leu Thr Gln
Leu Gly Ile Gln Met Pro 1170 1175 1180Ile Asp Asn Gly Leu Met Phe
Gly Val Ala Leu Ser Lys Asn His Ala1185 1190 1195 1200Asn Ala Glu
Phe Asn Glu Gly Val Asn Gly Lys Ser Asn Leu Leu Met 1205 1210
1215Ala Ser Leu Tyr Gly Lys Trp Gln Ser Gln Gln Gly Thr Phe Ile Ser
1220 1225 1230Leu Asp Gly Ser Tyr Gly Lys Ala Lys Asn Gln Leu Tyr
Leu Phe Gly 1235 1240 1245Glu Asn His Phe Thr Arg Arg Ile Ser Ser
Ile Gly Ala Asn Ile Gly 1250 1255 1260His Gln Phe Asp Leu Ala Gly
Val Gln Ile Gln Pro Thr Ile Gly Ala1265 1270 1275 1280Arg Tyr Tyr
His Phe Ser Gly Gln Asp Tyr Thr Leu Gly Gly Ala Lys 1285 1290
1295Ile Ser Ser Pro Asn Thr His Phe Met Thr Tyr Gln Ala Gly Leu Lys
1300 1305 1310Ala Ser Lys Thr Phe His Trp Met Thr Gly Lys Leu Asn
Gln Ala Leu 1315 1320 1325Gln Pro Thr Met Trp Met Gln Val Thr Asn
Ala 1330 1335162354DNAArtificial SequenceComplete deltaLKTCA with
original RBS 16gcattgaatt gatcaactaa tacttggttt ttcaagtgag
ttgcaatgcc taaaccatca 60ccaaaatagt ttggattatt gattttctcc cctacaaaat
ctagcccttc gtgttttctt 120gccatctcag ccaataccgg cacatcgcca
aaaatagcat caattcgccc attttgcaca 180tctaaaatag cattttgata
agaggcataa gatttcacat tgtactcttt tttctctttt 240gctaaatagt
gttggtaagt agtcccattt tgcacaccaa tcgttttcac cttagcaaaa
300tctgtatctt ttttcgcaat gaaggcagca gagcttggaa agtaaggctc
gctaaataat 360acttgtttct tacgtggttc cgtaataccc atacctgaaa
ttgcagcatc aaattgtttt 420tgttttaggc tttggattaa gctatcaaaa
ggttggctat ggaatgtaca atttgcattc 480atctctttac agatagcatt
tgcaatatcc acatcaaaac cgataatttc tcccttctct 540tcggtcattt
caaatggagg atagcttggc tccatcacaa atttgatatc ttgtgcctgc
600gcagtaacca cacacccgaa taaaagggtc aaaagtgttt ttttcataaa
aagtccctgt 660gttttcatta taaggattac cactttaacg cagttacttt
cttaaaaaaa gtcttctttt 720cataaagttt gttttatgtc atacaaacac
atcaaattga gatgtagttt ctcaatcctc 780ttgattcctc tatctcaaaa
aaacaaccca aaagaaaaaa gaaaagtata tgttacatta 840atattacaat
gtaattattt tgtttaattt ccctacattt tgtataactt taaaacactc
900ctttttctct tctgattata taaaagacaa aaaatacaat ttaagctaca
aaaaacaaca 960aaaaacaaca aaaaacacga caataagatc gagtaatgat
tatattatgt tataattttt 1020gacctaattt agaataatta tcgagtccaa
attatgaatc aattgaaagc tgttgaagaa 1080attatcggta catcacataa
cgatatcttt aaaggtagta agttcaatga tgcctttaac 1140ggtggtgatg
gtgtcgatac tattgacggt aacgacggca atgaccgctt atttggtggt
1200aaaggcgatg atattctcga tggtggaaat ggtgatgatt ttatcgatgg
cggtaaaggc 1260aacgacctat tacacggtgg caagggcgat gatattttcg
ttcaccgtaa aggcgatggt 1320aatgatatta ttaccgattc tgacggcaat
gataaattat cattctctga ttcgaactta 1380aaagatttaa catttgaaaa
agttaaacat aatcttgtca tcacgaatag caaaaaagag 1440aaagtgacca
ttcaaaactg gttccgagag gctgattttg ctaaagaagt gcctaattat
1500aaagcaacta aagatgagaa aatcgaagaa atcatcggtc aaaatggcga
gcggatcacc 1560tcaaagcaag ttgatgatct tatcgcaaaa ggtaacggca
aaattaccca agatgagcta 1620tcaaaagttg ttgataacta tgaattgctc
aaacatagca aaaatgtgac aaacagctta 1680gataagttaa tctcatctgt
aagtgcattt acctcgtcta atgattcgag aaatgtatta 1740gtggctccaa
cttcaatgtt ggatcaaagt ttatcttctc ttcaatttgc tagagcagct
1800taatttttaa tgattggcaa ctctatattg tttcacacat tatagagttg
ccgttttatt 1860ttataaaagg agacaatatg gaagctaacc atcaaaggaa
tgatcttggt ttagttgccc 1920tcactatgtt ggcacaatac cataatattt
cgcttaatcc ggaagaaata aaacataaat 1980ttgatcttga cggaaaaggg
ctttctttaa ctgcttggct tttagctgca aaatcgttag 2040cgttgaaagc
gaaacacatt aaaaaagaga tttcccgctt acacttggtg aatttaccgg
2100cattagtttg gcaagataac ggtaaacatt ttttattggt aaaagtggat
accgataata 2160accgctattt aacttacaat ttggaacaag atgctccaca
aattctgtca caagacgaat 2220ttgaagcctg ctatcaaggg cagttaattt
tggtcacgtc cagagcttcc gtagtaggtc 2280aattagcaaa gttcgatttc
acctggttta ttccggcggt gatcaaatac cgaaaaatct 2340ttctagaaac cttg
2354172354DNAArtificial SequenceComplete deltalktCA (with consensus
RBS) 17gcattgaatt gatcaactaa tacttggttt ttcaagtgag ttgcaatgcc
taaaccatca 60ccaaaatagt ttggattatt gattttctcc cctacaaaat ctagcccttc
gtgttttctt 120gccatctcag ccaataccgg cacatcgcca aaaatagcat
caattcgccc attttgcaca 180tctaaaatag cattttgata agaggcataa
gatttcacat tgtactcttt tttctctttt 240gctaaatagt gttggtaagt
agtcccattt tgcacaccaa tcgttttcac cttagcaaaa 300tctgtatctt
ttttcgcaat gaaggcagca gagcttggaa agtaaggctc gctaaataat
360acttgtttct tacgtggttc cgtaataccc atacctgaaa ttgcagcatc
aaattgtttt 420tgttttaggc tttggattaa gctatcaaaa ggttggctat
ggaatgtaca atttgcattc 480atctctttac agatagcatt tgcaatatcc
acatcaaaac cgataatttc tcccttctct 540tcggtcattt caaatggagg
atagcttggc tccatcacaa atttgatatc ttgtgcctgc 600gcagtaacca
cacacccgaa taaaagggtc aaaagtgttt ttttcataaa aagtccctgt
660gttttcatta taaggattac cactttaacg cagttacttt cttaaaaaaa
gtcttctttt 720cataaagttt gttttatgtc atacaaacac atcaaattga
gatgtagttt ctcaatcctc 780ttgattcctc tatctcaaaa aaacaaccca
aaagaaaaaa gaaaagtata tgttacatta 840atattacaat gtaattattt
tgtttaattt ccctacattt tgtataactt taaaacactc 900ctttttctct
tctgattata taaaagacaa aaaatacaat ttaagctaca aaaaacaaca
960aaaaacaaca aaaaacacga caataagatc gagtaatgat tatattatgt
tataattttt 1020gacctaattt agaataatta taggaggcaa attatgaatc
aattgaaagc tgttgaagaa 1080attatcggta catcacataa cgatatcttt
aaaggtagta agttcaatga tgcctttaac 1140ggtggtgatg gtgtcgatac
tattgacggt aacgacggca atgaccgctt atttggtggt 1200aaaggcgatg
atattctcga tggtggaaat ggtgatgatt ttatcgatgg cggtaaaggc
1260aacgacctat tacacggtgg caagggcgat gatattttcg ttcaccgtaa
aggcgatggt 1320aatgatatta ttaccgattc tgacggcaat gataaattat
cattctctga ttcgaactta 1380aaagatttaa catttgaaaa agttaaacat
aatcttgtca tcacgaatag caaaaaagag 1440aaagtgacca ttcaaaactg
gttccgagag gctgattttg ctaaagaagt gcctaattat 1500aaagcaacta
aagatgagaa aatcgaagaa atcatcggtc aaaatggcga gcggatcacc
1560tcaaagcaag ttgatgatct tatcgcaaaa ggtaacggca aaattaccca
agatgagcta 1620tcaaaagttg ttgataacta tgaattgctc aaacatagca
aaaatgtgac aaacagctta 1680gataagttaa tctcatctgt aagtgcattt
acctcgtcta atgattcgag aaatgtatta 1740gtggctccaa cttcaatgtt
ggatcaaagt ttatcttctc ttcaatttgc tagagcagct 1800taatttttaa
tgattggcaa ctctatattg tttcacacat tatagagttg ccgttttatt
1860ttataaaagg agacaatatg gaagctaacc atcaaaggaa tgatcttggt
ttagttgccc 1920tcactatgtt ggcacaatac cataatattt cgcttaatcc
ggaagaaata aaacataaat 1980ttgatcttga cggaaaaggg ctttctttaa
ctgcttggct tttagctgca aaatcgttag 2040cgttgaaagc gaaacacatt
aaaaaagaga tttcccgctt acacttggtg aatttaccgg 2100cattagtttg
gcaagataac ggtaaacatt ttttattggt aaaagtggat accgataata
2160accgctattt aacttacaat ttggaacaag atgctccaca aattctgtca
caagacgaat 2220ttgaagcctg ctatcaaggg cagttaattt tggtcacgtc
cagagcttcc gtagtaggtc 2280aattagcaaa gttcgatttc acctggttta
ttccggcggt gatcaaatac cgaaaaatct 2340ttctagaaac cttg
235418249PRTArtificial SequenceTranslation of deltaLKTCA 18Met Asn
Gln Leu Lys Ala Val Glu Glu Ile Ile Gly Thr Ser His Asn1 5 10 15Asp
Ile Phe Lys Gly Ser Lys Phe Asn Asp Ala Phe Asn Gly Gly Asp 20 25
30Gly Val Asp Thr Ile Asp Gly Asn Asp Gly Asn Asp Arg Leu Phe Gly
35 40 45Gly Lys Gly Asp Asp Ile Leu Asp Gly Gly Asn Gly Asp Asp Phe
Ile 50 55 60Asp Gly Gly Lys Gly Asn Asp Leu Leu His Gly Gly Lys Gly
Asp Asp65 70 75 80Ile Phe Val His Arg Lys Gly Asp Gly Asn Asp Ile
Ile Thr Asp Ser 85 90 95Asp Gly Asn Asp Lys Leu Ser Phe Ser Asp Ser
Asn Leu Lys Asp Leu 100 105 110Thr Phe Glu Lys Val Lys His Asn Leu
Val Ile Thr Asn Ser Lys Lys 115 120 125Glu Lys Val Thr Ile Gln Asn
Trp Phe Arg Glu Ala Asp Phe Ala Lys 130 135 140Glu Val Pro Asn Tyr
Lys Ala Thr Lys Asp Glu Lys Ile Glu Glu Ile145 150 155 160Ile Gly
Gln Asn Gly Glu Arg Ile Thr Ser Lys Gln Val Asp Asp Leu 165 170
175Ile Ala Lys Gly Asn Gly Lys Ile Thr Gln Asp Glu Leu Ser Lys Val
180 185 190Val Asp Asn Tyr Glu Leu Leu Lys His Ser Lys Asn Val Thr
Asn Ser 195 200 205Leu Asp Lys Leu Ile Ser Ser Val Ser Ala Phe Thr
Ser Ser Asn Asp 210 215 220Ser Arg Asn Val Leu Val Ala Pro Thr Ser
Met Leu Asp Gln Ser Leu225 230 235 240Ser Ser Leu Gln Phe Ala Arg
Ala Ala 24519372DNAP. multocida 19atgctactta tagataacgg tattccgatc
gcttattgta gttgggcaga tttaaacctt 60gagactgagg tgaaatatat taaggatatt
aattcgttaa caccagaaga atggcagtct 120ggtgacagac gctggattat
tgattgggta gcaccattcg gacattctca attactttat 180aaaaaaatgt
gtcagaaata ccctgatatg atcgtcagat ctatacgctt ttatccaaag
240cagaaagaat taggcaaaat tgcctacttt aaaggaggta aattagataa
aaaaacagca 300aaaaaacgtt ttgatacata tcaagaagag ctggcaacag
cacttaaaaa tgaatttaat 360tttattaaaa aa 37220124PRTP. multocida
20Met Leu Leu Ile Asp Asn Gly Ile Pro Ile Ala Tyr Cys Ser Trp Ala1
5 10 15Asp Leu Asn Leu Glu Thr Glu Val Lys Tyr Ile Lys Asp Ile Asn
Ser 20 25 30Leu Thr Pro Glu Glu Trp Gln Ser Gly Asp Arg Arg Trp Ile
Ile Asp 35 40 45Trp Val Ala Pro Phe Gly His Ser Gln Leu Leu Tyr Lys
Lys Met Cys 50 55 60Gln Lys Tyr Pro Asp Met Ile Val Arg Ser Ile Arg
Phe Tyr Pro Lys65 70 75 80Gln Lys Glu Leu Gly Lys Ile Ala Tyr Phe
Lys Gly Gly Lys Leu Asp 85 90 95Lys Lys Thr Ala Lys Lys Arg Phe Asp
Thr Tyr Gln Glu Glu Leu Ala 100 105 110Thr Ala Leu Lys Asn Glu Phe
Asn Phe Ile Lys Lys 115 120212859DNAP. multocida 21atgggaacta
gacttacaac cctatcaaat gggctaaaaa acactttaac ggcaaccaaa 60agtggcttac
ataaagccgg tcaatcatta acccaagccg gcagttcttt aaaaactggg
120gcaaaaaaaa ttatcctcta tattccccaa aattaccaat atgatactga
acaaggtaat 180ggtttacagg atttagtcaa agcggccgaa gagttgggga
ttgaggtaca aagagaagaa 240cgcaataata ttgcaacagc tcaaaccagt
ttaggcacga ttcaaaccgc tattggctta 300actgagcgtg gcattgtgtt
atccgctcca caaattgata aattgctaca gaaaactaaa 360gcaggccaag
cattaggttc tgccgaaagc attgtacaaa atgcaaataa agccaaaact
420gtattatctg gcattcaatc tattttaggc tcagtattgg
ctggaatgga tttagatgag 480gccttacaga ataacagcaa ccaacatgct
cttgctaaag ctggcttgga gctaacaaat 540tcattaattg aaaatattgc
taattcagta aaaacacttg acgaatttgg tgagcaaatt 600agtcaatttg
gttcaaaact acaaaatatc aaaggcttag ggactttagg agacaaactc
660aaaaatatcg gtggacttga taaagctggc cttggtttag atgttatctc
agggctatta 720tcgggcgcaa cagctgcact tgtacttgca gataaaaatg
cttcaacagc taaaaaagtg 780ggtgcgggtt ttgaattggc aaaccaagtt
gttggtaata ttaccaaagc cgtttcttct 840tacattttag cccaacgtgt
tgcagcaggt ttatcttcaa ctgggcctgt ggctgcttta 900attgcttcta
ctgtttctct tgcgattagc ccattagcat ttgccggtat tgccgataaa
960tttaatcatg caaaaagttt agagagttat gccgaacgct ttaaaaaatt
aggctatgac 1020ggagataatt tattagcaga atatcagcgg ggaacaggga
ctattgatgc atcggttact 1080gcaattaata ccgcattggc cgctattgct
ggtggtgtgt ctgctgctgc agccggctcg 1140gttattgctt caccgattgc
cttattagta tctgggatta ccggtgtaat ttctacgatt 1200ctgcaatatt
ctaaacaagc aatgtttgag cacgttgcaa ataaaattca taacaaaatt
1260gtagaatggg aaaaaaataa tcacggtaag aactactttg aaaatggtta
cgatgcccgt 1320tatcttgcga atttacaaga taatatgaaa ttcttactga
acttaaacaa agagttacag 1380gcagaacgtg tcatcgctat tactcagcag
caatgggata acaacattgg tgatttagct 1440ggtattagcc gtttaggtga
aaaagtcctt agtggtaaag cctatgtgga tgcgtttgaa 1500gaaggcaaac
acattaaagc cgataaatta gtacagttgg attcggcaaa cggtattatt
1560gatgtgagta attcgggtaa agcgaaaact cagcatatct tattcagaac
gccattattg 1620acgccgggaa cagagcatcg tgaacgcgta caaacaggta
aatatgaata tattaccaag 1680ctcaatatta accgtgtaga tagctggaaa
attacagatg gtgcagcaag ttctaccttt 1740gatttaacta acgttgttca
gcgtattggt attgaattag acaatgctgg aaatgtaact 1800aaaaccaaag
aaacaaaaat tattgccaaa cttggtgaag gtgatgacaa cgtatttgtt
1860ggttctggta cgacggaaat tgatggcggt gaaggttacg accgagttca
ctatagccgt 1920ggaaactatg gtgctttaac tattgatgca accaaagaga
ccgagcaagg tagttatacc 1980gtaaatcgtt tcgtagaaac cggtaaagca
ctacacgaag tgacttcaac ccataccgca 2040ttagtgggca accgtgaaga
aaaaatagaa tatcgtcata gcaataacca gcaccatgcc 2100ggttattaca
ccaaagatac cttgaaagct gttgaagaaa ttatcggtac atcacataac
2160gatatcttta aaggtagtaa gttcaatgat gcctttaacg gtggtgatgg
tgtcgatact 2220attgacggta acgacggcaa tgaccgctta tttggtggta
aaggcgatga tattctcgat 2280ggtggaaatg gtgatgattt tatcgatggc
ggtaaaggca acgacctatt acacggtggc 2340aagggcgatg atattttcgt
tcaccgtaaa ggcgatggta atgatattat taccgattct 2400gacggcaatg
ataaattatc attctctgat tcgaacttaa aagatttaac atttgaaaaa
2460gttaaacata atcttgtcat cacgaatagc aaaaaagaga aagtgaccat
tcaaaactgg 2520ttccgagagg ctgattttgc taaagaagtg cctaattata
aagcaactaa agatgagaaa 2580atcgaagaaa tcatcggtca aaatggcgag
cggatcacct caaagcaagt tgatgatctt 2640atcgcaaaag gtaacggcaa
aattacccaa gatgagctat caaaagttgt tgataactat 2700gaattgctca
aacatagcaa aaatgtgaca aacagcttag ataagttaat ctcatctgta
2760agtgcattta cctcgtctaa tgattcgaga aatgtattag tggctccaac
ttcaatgttg 2820gatcaaagtt tatcttctct tcaatttgct agagcagct
285922953PRTP. multocida 22Met Gly Thr Arg Leu Thr Thr Leu Ser Asn
Gly Leu Lys Asn Thr Leu1 5 10 15Thr Ala Thr Lys Ser Gly Leu His Lys
Ala Gly Gln Ser Leu Thr Gln 20 25 30Ala Gly Ser Ser Leu Lys Thr Gly
Ala Lys Lys Ile Ile Leu Tyr Ile 35 40 45Pro Gln Asn Tyr Gln Tyr Asp
Thr Glu Gln Gly Asn Gly Leu Gln Asp 50 55 60Leu Val Lys Ala Ala Glu
Glu Leu Gly Ile Glu Val Gln Arg Glu Glu65 70 75 80Arg Asn Asn Ile
Ala Thr Ala Gln Thr Ser Leu Gly Thr Ile Gln Thr 85 90 95Ala Ile Gly
Leu Thr Glu Arg Gly Ile Val Leu Ser Ala Pro Gln Ile 100 105 110Asp
Lys Leu Leu Gln Lys Thr Lys Ala Gly Gln Ala Leu Gly Ser Ala 115 120
125Glu Ser Ile Val Gln Asn Ala Asn Lys Ala Lys Thr Val Leu Ser Gly
130 135 140Ile Gln Ser Ile Leu Gly Ser Val Leu Ala Gly Met Asp Leu
Asp Glu145 150 155 160Ala Leu Gln Asn Asn Ser Asn Gln His Ala Leu
Ala Lys Ala Gly Leu 165 170 175Glu Leu Thr Asn Ser Leu Ile Glu Asn
Ile Ala Asn Ser Val Lys Thr 180 185 190Leu Asp Glu Phe Gly Glu Gln
Ile Ser Gln Phe Gly Ser Lys Leu Gln 195 200 205Asn Ile Lys Gly Leu
Gly Thr Leu Gly Asp Lys Leu Lys Asn Ile Gly 210 215 220Gly Leu Asp
Lys Ala Gly Leu Gly Leu Asp Val Ile Ser Gly Leu Leu225 230 235
240Ser Gly Ala Thr Ala Ala Leu Val Leu Ala Asp Lys Asn Ala Ser Thr
245 250 255Ala Lys Lys Val Gly Ala Gly Phe Glu Leu Ala Asn Gln Val
Val Gly 260 265 270Asn Ile Thr Lys Ala Val Ser Ser Tyr Ile Leu Ala
Gln Arg Val Ala 275 280 285Ala Gly Leu Ser Ser Thr Gly Pro Val Ala
Ala Leu Ile Ala Ser Thr 290 295 300Val Ser Leu Ala Ile Ser Pro Leu
Ala Phe Ala Gly Ile Ala Asp Lys305 310 315 320Phe Asn His Ala Lys
Ser Leu Glu Ser Tyr Ala Glu Arg Phe Lys Lys 325 330 335Leu Gly Tyr
Asp Gly Asp Asn Leu Leu Ala Glu Tyr Gln Arg Gly Thr 340 345 350Gly
Thr Ile Asp Ala Ser Val Thr Ala Ile Asn Thr Ala Leu Ala Ala 355 360
365Ile Ala Gly Gly Val Ser Ala Ala Ala Ala Gly Ser Val Ile Ala Ser
370 375 380Pro Ile Ala Leu Leu Val Ser Gly Ile Thr Gly Val Ile Ser
Thr Ile385 390 395 400Leu Gln Tyr Ser Lys Gln Ala Met Phe Glu His
Val Ala Asn Lys Ile 405 410 415His Asn Lys Ile Val Glu Trp Glu Lys
Asn Asn His Gly Lys Asn Tyr 420 425 430Phe Glu Asn Gly Tyr Asp Ala
Arg Tyr Leu Ala Asn Leu Gln Asp Asn 435 440 445Met Lys Phe Leu Leu
Asn Leu Asn Lys Glu Leu Gln Ala Glu Arg Val 450 455 460Ile Ala Ile
Thr Gln Gln Gln Trp Asp Asn Asn Ile Gly Asp Leu Ala465 470 475
480Gly Ile Ser Arg Leu Gly Glu Lys Val Leu Ser Gly Lys Ala Tyr Val
485 490 495Asp Ala Phe Glu Glu Gly Lys His Ile Lys Ala Asp Lys Leu
Val Gln 500 505 510Leu Asp Ser Ala Asn Gly Ile Ile Asp Val Ser Asn
Ser Gly Lys Ala 515 520 525Lys Thr Gln His Ile Leu Phe Arg Thr Pro
Leu Leu Thr Pro Gly Thr 530 535 540Glu His Arg Glu Arg Val Gln Thr
Gly Lys Tyr Glu Tyr Ile Thr Lys545 550 555 560Leu Asn Ile Asn Arg
Val Asp Ser Trp Lys Ile Thr Asp Gly Ala Ala 565 570 575Ser Ser Thr
Phe Asp Leu Thr Asn Val Val Gln Arg Ile Gly Ile Glu 580 585 590Leu
Asp Asn Ala Gly Asn Val Thr Lys Thr Lys Glu Thr Lys Ile Ile 595 600
605Ala Lys Leu Gly Glu Gly Asp Asp Asn Val Phe Val Gly Ser Gly Thr
610 615 620Thr Glu Ile Asp Gly Gly Glu Gly Tyr Asp Arg Val His Tyr
Ser Arg625 630 635 640Gly Asn Tyr Gly Ala Leu Thr Ile Asp Ala Thr
Lys Glu Thr Glu Gln 645 650 655Gly Ser Tyr Thr Val Asn Arg Phe Val
Glu Thr Gly Lys Ala Leu His 660 665 670Glu Val Thr Ser Thr His Thr
Ala Leu Val Gly Asn Arg Glu Glu Lys 675 680 685Ile Glu Tyr Arg His
Ser Asn Asn Gln His His Ala Gly Tyr Tyr Thr 690 695 700Lys Asp Thr
Leu Lys Ala Val Glu Glu Ile Ile Gly Thr Ser His Asn705 710 715
720Asp Ile Phe Lys Gly Ser Lys Phe Asn Asp Ala Phe Asn Gly Gly Asp
725 730 735Gly Val Asp Thr Ile Asp Gly Asn Asp Gly Asn Asp Arg Leu
Phe Gly 740 745 750Gly Lys Gly Asp Asp Ile Leu Asp Gly Gly Asn Gly
Asp Asp Phe Ile 755 760 765Asp Gly Gly Lys Gly Asn Asp Leu Leu His
Gly Gly Lys Gly Asp Asp 770 775 780Ile Phe Val His Arg Lys Gly Asp
Gly Asn Asp Ile Ile Thr Asp Ser785 790 795 800Asp Gly Asn Asp Lys
Leu Ser Phe Ser Asp Ser Asn Leu Lys Asp Leu 805 810 815Thr Phe Glu
Lys Val Lys His Asn Leu Val Ile Thr Asn Ser Lys Lys 820 825 830Glu
Lys Val Thr Ile Gln Asn Trp Phe Arg Glu Ala Asp Phe Ala Lys 835 840
845Glu Val Pro Asn Tyr Lys Ala Thr Lys Asp Glu Lys Ile Glu Glu Ile
850 855 860Ile Gly Gln Asn Gly Glu Arg Ile Thr Ser Lys Gln Val Asp
Asp Leu865 870 875 880Ile Ala Lys Gly Asn Gly Lys Ile Thr Gln Asp
Glu Leu Ser Lys Val 885 890 895Val Asp Asn Tyr Glu Leu Leu Lys His
Ser Lys Asn Val Thr Asn Ser 900 905 910Leu Asp Lys Leu Ile Ser Ser
Val Ser Ala Phe Thr Ser Ser Asn Asp 915 920 925Ser Arg Asn Val Leu
Val Ala Pro Thr Ser Met Leu Asp Gln Ser Leu 930 935 940Ser Ser Leu
Gln Phe Ala Arg Ala Ala945 950232124DNAP. multocida 23atggaagcta
accatcaaag gaatgatctt ggtttagttg ccctcactat gttggcacaa 60taccataata
tttcgcttaa tccggaagaa ataaaacata aatttgatct tgacggaaaa
120gggctttctt taactgcttg gcttttagct gcaaaatcgt tagcgttgaa
agcgaaacac 180attaaaaaag agatttcccg cttacacttg gtgaatttac
cggcattagt ttggcaagat 240aacggtaaac attttttatt ggtaaaagtg
gataccgata ataaccgcta tttaacttac 300aatttggaac aagatgctcc
acaaattctg tcacaagacg aatttgaagc ctgctatcaa 360gggcagttaa
ttttggtcac gtccagagct tccgtagtag gtcaattagc aaagttcgat
420ttcacctggt ttattccggc ggtgatcaaa taccgaaaaa tctttctaga
aaccttgatt 480gtttcgatct ttttgcaaat ttttgcccta attacaccgc
tattcttcca agttgttatg 540gataaagtac tggtgcatcg aggtttttca
accttgaata tcattacggt tgccttagct 600attgtgatca tctttgaaat
tgtactaagt ggtttgagaa cctatgtttt ttctcatagc 660actagccgta
ttgatgttga attaggcgct aaattatttc gacatttatt atcactaccc
720atttcttatt ttgaaaacag acgagttgga gatacagtcg ctagggttag
agaattagat 780caaattcgta atttccttac cggacaagca ttaacctcgg
tgttagatct cttattctct 840tttatctttt ttgccgtaat gtggtattac
agcccaaaat taaccttggt aattcttggt 900tcattgccct gctatatttt
atggtcaatt tttattagtc cgattttaag acggcgttta 960gatgagaaat
ttgcccgaag tgctgataac caagcattct tagttgagtc ggtaacagcc
1020atcaatatga ttaaagcgat ggcggttgct ccacaaatga cggatacatg
ggataaacag 1080ctggcaagct atgtttcatc aagtttccgt gtcaccgtat
tagcaaccat tgggcaacaa 1140ggtgtacaac ttattcaaaa aaccgttatg
gtgattaacc tttggttagg ggcacactta 1200gttatttcag gcgatctgag
tattgggcaa ttaattgcct ttaatatgct atcagggcaa 1260gtgattgcac
cggtgattcg gctggctcag ctctggcaag atttccaaca agttgggatt
1320tccgtcactc gcttaggtga tgttttaaac tctccaaccg aacaatatca
aggcaaatta 1380tcactaccag aaataaaagg cgatatctca tttaaaaata
tccgctttag atataaacca 1440gatgcaccaa ctattttaaa taatgtgaat
ttagaaatta ggcaaggaga agtgattggg 1500attgttggac gttccggttc
aggcaaaagt actctgacta aattactgca acgtttttat 1560attcctgaaa
atgggcaggt tttgattgat ggacatgatc tagccttagc tgatccaaac
1620tggctacgcc gtcaaatagg tgtagtgctg caagataatg tgttattaaa
ccgcagtatc 1680cgagaaaata ttgcgctatc agatccagga atgccaatgg
agcgagtaat ttatgcagca 1740aaattagcag gggctcacga ttttatttca
gaattgcgtg aaggttataa caccattgtg 1800ggtgaacaag gagcggggct
ttcaggcggg caacgccaac ggattgcgat tgctcgagct 1860ttggtaaaca
acccgaaaat cctgattttt gatgaggcaa ccagtgccct cgattacgaa
1920tctgagcata ttattatgca aaatatgcaa aaaatatgcc aaggcagaac
cgtgattttg 1980attgcacatc gtttatcgac cgtcaaaaat gcggatcgaa
ttattgtgat ggaaaagggg 2040gaaattgttg agcaaggcaa gcaccacgaa
ttactgcaaa acagtaacgg actttattcc 2100tacttacacc aattacaact taat
212424708PRTP. multocida 24Met Glu Ala Asn His Gln Arg Asn Asp Leu
Gly Leu Val Ala Leu Thr1 5 10 15Met Leu Ala Gln Tyr His Asn Ile Ser
Leu Asn Pro Glu Glu Ile Lys 20 25 30His Lys Phe Asp Leu Asp Gly Lys
Gly Leu Ser Leu Thr Ala Trp Leu 35 40 45Leu Ala Ala Lys Ser Leu Ala
Leu Lys Ala Lys His Ile Lys Lys Glu 50 55 60Ile Ser Arg Leu His Leu
Val Asn Leu Pro Ala Leu Val Trp Gln Asp65 70 75 80Asn Gly Lys His
Phe Leu Leu Val Lys Val Asp Thr Asp Asn Asn Arg 85 90 95Tyr Leu Thr
Tyr Asn Leu Glu Gln Asp Ala Pro Gln Ile Leu Ser Gln 100 105 110Asp
Glu Phe Glu Ala Cys Tyr Gln Gly Gln Leu Ile Leu Val Thr Ser 115 120
125Arg Ala Ser Val Val Gly Gln Leu Ala Lys Phe Asp Phe Thr Trp Phe
130 135 140Ile Pro Ala Val Ile Lys Tyr Arg Lys Ile Phe Leu Glu Thr
Leu Ile145 150 155 160Val Ser Ile Phe Leu Gln Ile Phe Ala Leu Ile
Thr Pro Leu Phe Phe 165 170 175Gln Val Val Met Asp Lys Val Leu Val
His Arg Gly Phe Ser Thr Leu 180 185 190Asn Ile Ile Thr Val Ala Leu
Ala Ile Val Ile Ile Phe Glu Ile Val 195 200 205Leu Ser Gly Leu Arg
Thr Tyr Val Phe Ser His Ser Thr Ser Arg Ile 210 215 220Asp Val Glu
Leu Gly Ala Lys Leu Phe Arg His Leu Leu Ser Leu Pro225 230 235
240Ile Ser Tyr Phe Glu Asn Arg Arg Val Gly Asp Thr Val Ala Arg Val
245 250 255Arg Glu Leu Asp Gln Ile Arg Asn Phe Leu Thr Gly Gln Ala
Leu Thr 260 265 270Ser Val Leu Asp Leu Leu Phe Ser Phe Ile Phe Phe
Ala Val Met Trp 275 280 285Tyr Tyr Ser Pro Lys Leu Thr Leu Val Ile
Leu Gly Ser Leu Pro Cys 290 295 300Tyr Ile Leu Trp Ser Ile Phe Ile
Ser Pro Ile Leu Arg Arg Arg Leu305 310 315 320Asp Glu Lys Phe Ala
Arg Ser Ala Asp Asn Gln Ala Phe Leu Val Glu 325 330 335Ser Val Thr
Ala Ile Asn Met Ile Lys Ala Met Ala Val Ala Pro Gln 340 345 350Met
Thr Asp Thr Trp Asp Lys Gln Leu Ala Ser Tyr Val Ser Ser Ser 355 360
365Phe Arg Val Thr Val Leu Ala Thr Ile Gly Gln Gln Gly Val Gln Leu
370 375 380Ile Gln Lys Thr Val Met Val Ile Asn Leu Trp Leu Gly Ala
His Leu385 390 395 400Val Ile Ser Gly Asp Leu Ser Ile Gly Gln Leu
Ile Ala Phe Asn Met 405 410 415Leu Ser Gly Gln Val Ile Ala Pro Val
Ile Arg Leu Ala Gln Leu Trp 420 425 430Gln Asp Phe Gln Gln Val Gly
Ile Ser Val Thr Arg Leu Gly Asp Val 435 440 445Leu Asn Ser Pro Thr
Glu Gln Tyr Gln Gly Lys Leu Ser Leu Pro Glu 450 455 460Ile Lys Gly
Asp Ile Ser Phe Lys Asn Ile Arg Phe Arg Tyr Lys Pro465 470 475
480Asp Ala Pro Thr Ile Leu Asn Asn Val Asn Leu Glu Ile Arg Gln Gly
485 490 495Glu Val Ile Gly Ile Val Gly Arg Ser Gly Ser Gly Lys Ser
Thr Leu 500 505 510Thr Lys Leu Leu Gln Arg Phe Tyr Ile Pro Glu Asn
Gly Gln Val Leu 515 520 525Ile Asp Gly His Asp Leu Ala Leu Ala Asp
Pro Asn Trp Leu Arg Arg 530 535 540Gln Ile Gly Val Val Leu Gln Asp
Asn Val Leu Leu Asn Arg Ser Ile545 550 555 560Arg Glu Asn Ile Ala
Leu Ser Asp Pro Gly Met Pro Met Glu Arg Val 565 570 575Ile Tyr Ala
Ala Lys Leu Ala Gly Ala His Asp Phe Ile Ser Glu Leu 580 585 590Arg
Glu Gly Tyr Asn Thr Ile Val Gly Glu Gln Gly Ala Gly Leu Ser 595 600
605Gly Gly Gln Arg Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Asn Asn
610 615 620Pro Lys Ile Leu Ile Phe Asp Glu Ala Thr Ser Ala Leu Asp
Tyr Glu625 630 635 640Ser Glu His Ile Ile Met Gln Asn Met Gln Lys
Ile Cys Gln Gly Arg 645 650 655Thr Val Ile Leu Ile Ala His Arg Leu
Ser Thr Val Lys Asn Ala Asp 660 665 670Arg Ile Ile Val Met Glu Lys
Gly Glu Ile Val Glu Gln Gly Lys His 675 680 685His Glu Leu Leu Gln
Asn Ser Asn Gly Leu Tyr Ser Tyr Leu His Gln 690 695 700Leu Gln Leu
Asn705251434DNAP. multocida 25atgaaaatat ggcttagtgg tatttatgaa
tttttcctac gctataaaaa catttgggca 60gaagtatgga aaattcgtaa agaattagac
cacccaaaca gaaaaaaaga cgaaagtgaa 120tttttaccgg cacatttaga
actgattgaa accccggttt ctaaaaaacc acgtctaatt 180gcttatttga
ttatgctatt tttagttgtg gcaattgtgc ttgccagtgt aagcaaagtt
240gaaattgtgg cgactgctcc cggtaaatta acttttagtg gcagaagtaa
agaaattaaa 300ccgattgaaa acgccattgt
acaagaaatt ttcgttaaag atgggcagtt tgtggaaaaa 360gggcaattat
tagtcagctt aactgcattg ggttctgatg cagatatcaa aaagaccatg
420gcttcacttt ctttagctaa actggagaac tatcgctacc aaactttgct
tactgccatt 480gaaaaagagt ccttgccggt gattgattta tctagaaccg
aatttaaaga ttcatcggaa 540gaagatcgac tacgtattaa acacttaatt
gaggagcaat acaccacttg gcaaaaacaa 600aaaacacaga aaactttagc
gtataagcgt aaagaggctg aaaaacaaac aatatttgcc 660tatgtccgta
aatatgaagg tgcaacacgt attgaacaag aaaaattaaa agactttaag
720gcactttata aacagaagtc tttatctaag cacgaacttc ttgcgcaaga
aaataaatta 780attgaggctc agaatgagct agctgtttat cgctcaaaat
taaatgaatt agaaaatgat 840ctactcaatg taaaagaaga acttgaattg
atcacgcaat tctttaaaag cgatgtgttg 900gaaaaattaa agcaacatat
tgaaaatgaa cgccaacttc ggctcgagtt agaaaaaaat 960aatcaacgca
gacaggcctc gatgatcaga gcaccggttt ccggtacggt tcagcaactg
1020aaaattcaca ctataggtgg tgttgttacg actgctgaaa ccttgatgat
cattgtgccg 1080gaagacgatg tgttagaggc caccgctctg gttccaaaca
aagatatcgg ctttgttgca 1140gcagggcagg aggtgattat taaagtggaa
actttccctt atacacgcta tggttatcta 1200actggtcgaa ttaaacatat
tagcccggat gcgattgaac aacctaatgt aggcttagtt 1260tttaatgcaa
ctatagctat agataggaag aatctaacat cgcctgatgg gcgaaaaatt
1320gatttgagtt caggtatgac aataactgct gaaatcaaaa ccggtgaacg
gagtgtaatg 1380agttatttac tcagcccatt agaagaatct gtcacagaaa
gtttaaggga acgc 143426478PRTP. multocida 26Met Lys Ile Trp Leu Ser
Gly Ile Tyr Glu Phe Phe Leu Arg Tyr Lys1 5 10 15Asn Ile Trp Ala Glu
Val Trp Lys Ile Arg Lys Glu Leu Asp His Pro 20 25 30Asn Arg Lys Lys
Asp Glu Ser Glu Phe Leu Pro Ala His Leu Glu Leu 35 40 45Ile Glu Thr
Pro Val Ser Lys Lys Pro Arg Leu Ile Ala Tyr Leu Ile 50 55 60 Met
Leu Phe Leu Val Val Ala Ile Val Leu Ala Ser Val Ser Lys Val65 70 75
80Glu Ile Val Ala Thr Ala Pro Gly Lys Leu Thr Phe Ser Gly Arg Ser
85 90 95Lys Glu Ile Lys Pro Ile Glu Asn Ala Ile Val Gln Glu Ile Phe
Val 100 105 110Lys Asp Gly Gln Phe Val Glu Lys Gly Gln Leu Leu Val
Ser Leu Thr 115 120 125Ala Leu Gly Ser Asp Ala Asp Ile Lys Lys Thr
Met Ala Ser Leu Ser 130 135 140Leu Ala Lys Leu Glu Asn Tyr Arg Tyr
Gln Thr Leu Leu Thr Ala Ile145 150 155 160Glu Lys Glu Ser Leu Pro
Val Ile Asp Leu Ser Arg Thr Glu Phe Lys 165 170 175Asp Ser Ser Glu
Glu Asp Arg Leu Arg Ile Lys His Leu Ile Glu Glu 180 185 190Gln Tyr
Thr Thr Trp Gln Lys Gln Lys Thr Gln Lys Thr Leu Ala Tyr 195 200
205Lys Arg Lys Glu Ala Glu Lys Gln Thr Ile Phe Ala Tyr Val Arg Lys
210 215 220Tyr Glu Gly Ala Thr Arg Ile Glu Gln Glu Lys Leu Lys Asp
Phe Lys225 230 235 240Ala Leu Tyr Lys Gln Lys Ser Leu Ser Lys His
Glu Leu Leu Ala Gln 245 250 255Glu Asn Lys Leu Ile Glu Ala Gln Asn
Glu Leu Ala Val Tyr Arg Ser 260 265 270Lys Leu Asn Glu Leu Glu Asn
Asp Leu Leu Asn Val Lys Glu Glu Leu 275 280 285Glu Leu Ile Thr Gln
Phe Phe Lys Ser Asp Val Leu Glu Lys Leu Lys 290 295 300Gln His Ile
Glu Asn Glu Arg Gln Leu Arg Leu Glu Leu Glu Lys Asn305 310 315
320Asn Gln Arg Arg Gln Ala Ser Met Ile Arg Ala Pro Val Ser Gly Thr
325 330 335Val Gln Gln Leu Lys Ile His Thr Ile Gly Gly Val Val Thr
Thr Ala 340 345 350Glu Thr Leu Met Ile Ile Val Pro Glu Asp Asp Val
Leu Glu Ala Thr 355 360 365Ala Leu Val Pro Asn Lys Asp Ile Gly Phe
Val Ala Ala Gly Gln Glu 370 375 380Val Ile Ile Lys Val Glu Thr Phe
Pro Tyr Thr Arg Tyr Gly Tyr Leu385 390 395 400Thr Gly Arg Ile Lys
His Ile Ser Pro Asp Ala Ile Glu Gln Pro Asn 405 410 415Val Gly Leu
Val Phe Asn Ala Thr Ile Ala Ile Asp Arg Lys Asn Leu 420 425 430Thr
Ser Pro Asp Gly Arg Lys Ile Asp Leu Ser Ser Gly Met Thr Ile 435 440
445Thr Ala Glu Ile Lys Thr Gly Glu Arg Ser Val Met Ser Tyr Leu Leu
450 455 460Ser Pro Leu Glu Glu Ser Val Thr Glu Ser Leu Arg Glu
Arg465 470 475
* * * * *